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Referat: 
Die vorliegende Studie präsentiert und evaluiert einen diagnostischen Ansatz zur quantitativen
Bestimmung von metabolomischen Markern von Prostatakrebs, basierend auf der Durchführung von 
"1H High Resolution Magic Angle Spinning Nuclear Magnetic Resonance Spectroscopy" (1H HRMAS 
NMR Spektroskopie) und quantitativer Immunhistochemie. 
Durch Untersuchung von Gewebsproben von Prostatakrebspatienten mittels 1H HRMAS NMR 
Spektroskopie und anschließender Korrelation der Ergebnisse mit quantitativ bestimmten Resultaten 
immunhistochemischer Färbeverfahren können die Metaboliten Phosphocholin und Zitrat in der 
vorliegenden Patientenkohorte als potentielle metabolomische Marker von Prostatakrebs identifiziert 
werden. Eine Validierung der vorgestellten diagnostischen Methode erfolgt durch vergleichende 
Analysen qualitativer und quantitativer konventioneller histopathologischer Untersuchungen.  
Die Anwendung des präsentierten diagnostischen Ansatzes erfolgt zusätzlich zur Bestimmung von 
potentiellen metabolomischen Markern von rezidivierenden Prostatakrebserkrankungen. 
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1 Introduction 
1. 1 Prostate Cancer 
Prostate cancer (PCa) is the most frequently diagnosed malignant disease among adult males 
in the USA and the second leading cause of cancer-related deaths in men [1]. Worldwide, the 
5-year prevalence of PCa has been calculated at more than 3.9 million cases [2]. The 
distribution of incidence is very heterogeneous and highest rates are found in industrialized 
countries, especially of Northern America, Western and Northern Europe and Australia. With 
233,000 newly diagnosed cases and about 29,480 cancer associated deaths among males in 
the USA estimated for 2013, PCa presents a tremendous and significant health problem [1]. 
The lifetime risk of developing PCa for American men is approximately 15%. However, 
autopsies have revealed microscopic prostate carcinomas in up to 29% in the age group of  
30- 40 year old men and 64% in age group 60- 70 years. At 80 years of age, as many as 80% 
of all men show small carcinomas [3].The risk of developing PCa is known to be related to 
genetic factors, diet, lifestyle and androgens. Furthermore, studies indicated that infection or 
inflammation of the prostate may also trigger PCa development and that environmental 
carcinogens might promote PCa progression [3]. High risk groups have been identified within 
the population, including African Americans as well as men with one or more first-degree 
relatives diagnosed with PCa at an early age [1]. 
Histology indicates that more than 95% of PCas are unevenly distributed, epithelially derived 
adenocarcinomas of which more than 75% are located in the peripheral zone, 10-15% in the 
transition zone and less than 15% in the central zone of the prostate [4]. This cancer tends to 
metastasize to the bones, especially the lumbar spine, pelvis and femur. Bone metastases can 
be found in up to 70% of patients with advanced PCa [5]. In general, this malignancy  is 
characterized by a relatively slow growth rate of the primary tumor, compared to malignant 
transformations of other organs [6]. Given the mostly indolent clinical behavior of PCa, an 
early and accurate diagnosis is crucial, in order to provide an adequate treatment for this 
highly prevalent disease.  
�
1. 2  Detection of Prostate Cancer – State of the Art 
The detection of PCa according to the screening guidelines of the American Cancer Society 
includes a serum Prostate-Specific Antigen (PSA) test and annual Digital Rectal Examination 
(DRE) for men older than 50 years. High risk groups are subjected to earlier screening tests at 
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an age of 45 years [7]. Clinical tools that are administered to symptomatic patients in order to 
detect PCa are transrectal ultrasound (TRUS) and, less frequently, Magnetic Resonance 
Imaging (MRI) [4]. The gold standard of modern PCa diagnosis, however, is the 
histopathological examination of transrectal ultrasound-guided core biopsies [8]. 
1. 2. 1 Prostate- Specific Antigen Test and Digital Rectal Examination 
Despite the high prevalence of PCa in the USA, the 5-year relative survival rate for localized 
or locally advanced disease is nearly 100% [7]. This is mainly due to the development of 
prostate-specific antigen (PSA) screening tests in the 1990s, which resulted in a remarkable 
increase in the incidence of early diagnosed PCas [9]. PSA is a glycoprotein produced by the 
cells of the prostate gland and added to the ejaculate, where it functions as a liquefier of the 
semen. Although there is no true PSA cut-off point distinguishing cancer from non-cancerous 
conditions, an elevated level of PSA (> 4 ng/ml) in the serum has been shown to correlate 
with the occurrence of PCa. However, while PSA is prostate specific, it is not cancer specific: 
benign prostate hyperplasia (BPH) and prostatitis are conditions that are known to increase 
serum PSA levels, thereby leading to diagnostic uncertainty [10, 11]. While significantly 
increasing the number of early PCa diagnoses, the PSA screening lacks the ability to 
distinguish more aggressive and malignant tumors from indolent cases, leading to 
overdiagnosis and overtreatment [12, 13]. Even though studies indicated that PSA-based 
screening might reduce mortality rates [14, 15], recent systematic reviews failed to find 
significant evidence for that [16]. 
DRE, a routine clinical method used to screen for suspicious prostate structures, is another 
insufficient diagnostic tool, due to its lack of specificity and high investigator-dependence. 
Benign conditions, such as BPH, can cause abnormal test results, leading to further diagnosis 
and, oftentimes, unnecessary intervention. Only about 25-50% of abnormal findings in DRE 
can ultimately be verified as PCa [10]. 
1.2.2 Radiographic Methods in PCa Detection 
Radiographic methods for PCa diagnostics are commonly conducted on patients with elevated 
PSA levels and abnormal findings in DRE. 
Magnetic Resonance Imaging (MRI) represents a non-invasive approach to obtain images of 
anatomical structures in the prostate. For that, the patient is placed in a large superconducting 
magnet- the MRI scanner- at field strengths of 1.5 or 3 Tesla. A combination of pelvic and 
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endorectal coils is used for induction of a current that can then be translated into anatomical 
images. More detailed information on the scientific background of magnetic resonance is 
illustrated in Chapter 2. Cancerous prostate tissue is typically assessed using conventional 
MRI sequences, such as T2-weighted (spin-spin relaxation time) imaging and T1-weighted 
(spin-lattice relaxation time) sequences before and after the injection of a gadolinium-based 
contrast agent (Figure 1). Due to an increase of cell density in pathologic cells and a 
consecutive decrease in water content, prostate cancer tissue appears with decreased signal 
intensity on T2-weighted imaging. 
Figure 1: MRI scans of a human prostate with a cancerous lesion: (A) Axial T1-weighted and (B) 
axial T2-weighted images. The red arrows point at the malignant neoplasm, which is located in the 
peripheral zone [17]. 
However, the interpretation of MR images can be biased by non-malignant conditions, and 
even large tumors (> 0.5cm3) can be detected by MRI in only approximately 70% [18]. Thus, 
prostate MRI serves to increase the accuracy of histopathology by identifying a specific target 
area for biopsy, rather than presenting an alternative diagnostic method [19]. The use of 
advanced MRI techniques, such as diffusion weighted imaging (DWI), perfusion weighted 
imaging (PWI) or the use of the apparent diffusion coefficient (ADC) to predict prostate 
cancer volume, could aid in increasing diagnostic accuracy in the future [20].  
Nuclear Magnetic Resonance Spectroscopy (MRS) adds additional information to anatomical 
imaging by identifying metabolites in biological tissues. Malignant conditions, like PCa, can 
thus be distinguished from benign conditions due to metabolic changes (Figure 2). However, 
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none of these technologies fully reveal the extent of prostate cancer. At present, the focus 
shifts to multi-parametrical imaging to improve the diagnostic sensitivity and specificity. The 
evaluation and interpretation of these data sets depend on the contributions of expert 
radiologists and MRI scientists. Novel objective radiological methods that can be employed 
for routine diagnostics in a clinical setting are highly needed. 
Figure 2: Magnetic resonance spectroscopy of a prostate cancer. The left panel (H) shows a 
spectrum acquired from the right peripheral zone with a prominent citrate peak and relatively low 
choline signal, indicative of healthy tissue.  The right panel (T) shows a reduced citrate signal and 
an increase in choline in tumor tissue of the left peripheral zone [21]. 
1.2.3 Transrectal Core Biopsies and Histopathological Analysis
The gold standard of modern PCa detection is the performance of transrectal ultrasound-
guided biopsies (TRUS) with subsequent histopathological analysis of the obtained tissue 
samples. This invasive method, first described in 1937 by Astraldi [22], is conducted to 
confirm suspicious findings in the clinical tests, such as elevated levels of PSA or an 
abnormal DRE. For initial biopsies, an ultrasound probe is inserted through the lining of the 
rectum to guide several small needles through the rectum wall into suspicious areas of the 
prostate. Traditionally, six or twelve tissue cores are obtained in one intervention [10]. 
���
�
Unfortunately, this method shows low sensitivity, a high sampling error and high false-
negative rates, detecting PCa in only 22-34% of the initial biopsy [23, 24]. For the 
histopathological evaluation of core biopsies, the GLEASON score is used and will be further 
described in the subsequent section. 
1.2.4 Histopathological Grading of Prostate Cancer: GLEASON Score 
The GLEASON score describes a histopathological grading system developed by Donald 
Gleason, which is used in prostate cancer staging, to determine prognosis and guide 
therapy[25]. Based on tissue obtained from prostate biopsies or prostatectomies, histological 
grades are assigned to the most common and second most common patterns that appear in the 
tissue. Both grades are added to obtain the final GLEASON score. The GLEASON patterns 
are associated with characteristic features, ranging from well differentiated (Grade 1) to 
poorly differentiated (Grade 5, Figure 3). The GLEASON grading system is currently the 
most widely used clinical grading system worldwide. Its clinical importance is due to the fact 
that the GLEASON score has been shown to be a prognostic marker, found to be closely 
associated with malignancy, overall survival and recurrence of disease [26, 27]. 
A       B 
Figure 3: The GLEASON score is a histopathological grading system used for PCa staging. 
Description (A) and illustration (B) of the histological appearance of the GLEASON grades as 
determined by Donald Gleason 1966 [25, 28].
Grade Description 
1 
Tissue closely resembles normal tissue. 
Prostate glands appear small, well-
formed and closely packed. 
2 
Prostate glands appear well-formed but 
enlarged and more spaced out. 
3 
Glands are distinguishable but cells 
appear darker and begin to invade 
surrounding tissue. 
4 
Glands are distinguishable but cells 
appear darker and begin to invade 
surrounding tissue. 
5 No recognizable glands, sheets of cells. 
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1.3 Challenges and Need for New Approaches in PCa Diagnostic Management 
About 158,000 prostatectomy procedures are performed each year in the USA because of 
clinical suspicion of PCa [29].  Radical treatment procedures, like prostatectomies, often 
result in impotence and /or incontinence of urine, causing enormous impact on the quality of 
life for patients [30]. 
While routine diagnostic methods, most importantly the PSA screening test, have greatly 
improved early diagnosis and led to a tremendous increase in early onset of treatment, they 
are also responsible for a substantial number of unnecessary interventions in a tumor type that 
often exhibits indolent, slow growth. About 67% of the cancers managed with radical 
procedures would never have led to the patient’s death and, therefore, would not have 
required such a radical treatment [31-33]. 
None of the currently available diagnostic tools has the potential to accurately distinguish 
between highly aggressive and malignant tumors, which require consequent treatment, and 
indolent low malignant cases, which can be managed by regular observation without reaching 
clinical significance during the patient’s lifetime. 
Therefore, new diagnostic methods to determine biological status, malignant potential, and 
extent of the disease are urgently needed in order to optimize diagnosis and ultimately 
minimize healthcare costs.  
“High Resolution Magic Angle Spinning Nuclear Magnetic Resonance Spectroscopy”  
(1H HRMAS MRS), a method introduced for intact biological tissue analysis in 1996 [34, 35], 
has proven to be a candidate to address the current challenges present in PCa diagnostics [36]. 
This method measures metabolomic profiles while preserving tissue architecture for 
subsequent evaluations of histopathology [37]. To date, metabolomic profiles established by 
1H HRMAS MRS have been evaluated and validated using conventional histopathology as the 
reference standard. In contrast to conventional histopathology, immunohistochemistry (IHC) 
presents an objective and observer-independent diagnostic method [38, 39]. Since IHC has the 
potential to provide more objective, accurate and quantitative measures of tissue pathology 
than routine histopathology, the present study attempted to establish a novel quantitative and 
observer-independent diagnostic approach by exploring the potential of prostate cancer 
immunomarkers to quantify metabolomic profiles established by 1H HRMAS MRS. 
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2 Scientific Background I: Nuclear Magnetic Resonance,
1
H HRMAS 
 NMR Spectroscopy and Metabolomic Profiles 
2.1  Nuclear Magnetic Resonance 
Nuclear magnetic resonance (NMR) describes a physical phenomenon that is based on the 
fact that several atomic nuclei have intrinsic magnetic moments and can therefore absorb and 
re-emit electromagnetic radiation when placed in a magnetic field. 
All subatomic particles (protons, electrons and neutrons) have an intrinsic quantum 
mechanical property, the spin I. Associated with the spin is a nuclear angular momentum l
which has the total amplitude of: 
���� � ���� � �� ����
The constant h necessary for the calculation of the nuclear angular momentum is called 
Planck’s constant and equals 6.6262 10-34 Js.  
If the number of neutrons and protons in an atomic nucleus are both even, the overall nuclear 
spin I equals 0, as an even number of spins in an atom pair up and cancel each other. 
However, if either the number of neutrons or protons are odd, a non-vanishing overall spin 
results, which is either an integer number - if both proton and neutron numbers are odd- or a 
half-integer number- if the sum of numbers of protons and neutrons is odd. Isotopes with an 
overall spin have an intrinsic magnetic moment µ. The magnetic moment is proportional to 
the nuclear angular momentum. 
� � �� � ���
The gyromagnetic ratio � is a characteristic constant for each nucleus.  
For protons, � = 2.675×108 s-1T-1. 
Without an external magnetic field, a nuclear state with a spin quantum number I is (2I+1) - 
fold degenerate, which means it has (2I+1) nuclear spin levels with the same energy. 
Therefore, at thermal equilibrium, the distribution of magnetic moments is completely 
isotropic, meaning that the number of atoms in each of the states will be equal.  
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However, if an external magnetic field B0 is applied to a nuclear state with an overall spin 
quantum number I, a splitting into (2I+1) nuclear spin levels with different energy occurs. 
This phenomenon is called Zeeman Splitting or Zeeman Effect (Figure 4). 
Figure 4: Energy level diagram of a spin ½ in the presence of an external magnetic field. 
Illustration of the phenomenon of Zeeman-splitting: In an external magnetic field B0, a splitting 
into different nuclear energy levels (m= ±1/2) occurs for a proton spin [40]. 
The energy E in each level can be calculated as follows: 
�� � ������� ��
In nuclei with an overall spin I of one-half, like protons (1H, but also 13C, 15N, 19F and 31P), a 
Zeeman splitting into two distinct energy levels (nuclear spin levels) occurs: 
 m = ½ or m = -½. 
The intrinsic magnetic moment will align either with (parallel) or against (anti-parallel) the 
magnetic field B0. The energetically preferred parallel spin state m = ½ is called �-state, 
while the anti-parallel oriented higher energy level is referred to as ß-state.  
Boltzmann has described the distribution of atoms into the energy states at thermal 
equilibrium.
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The number of atoms N1 in the anti-parallel state � and N0 in the parallel state � at a 
designated temperature T can be calculated through the Boltzmann distribution equation: 
��
�� � ��
����������
The Boltzmann constant k equals 1.3806 10-23 J/K. 
For positive �, the lower-energy state � is slightly more populated than the higher-energy 
level �. The sum of the angular momentums creates a macroscopic magnetization, which is 
used in NMR spectroscopy. The differences in the population of the α and β energy levels is 
called spin polarization, and represents a necessary requirement for NMR spectroscopy. 
Higher �, lower temperature and a greater magnetic field strength B0 contribute to a greater 
energy level separation and enhance the sensitivity of the NMR spectra.  
2.1.1  Spin Precession 
The rotational axis of a spin in an external magnetic field cannot align itself exactly with the 
direction of the field. Instead, only the z-component of the spin is aligned with the external 
field B0 and the x and y components are not defined according to the Heisenberg’s uncertainty 
principle [41]. Consequently, the field exerts a torque on the magnetic moment of a spin, 
causing it to move around the field on a cone in a constant angle between the magnetic 
moment and the external magnetic field (Figure 5). 
Figure 5:  Cartoon representation of nuclear spin precession induced by the external magnetic 
field. B0 represents the direction of the field, m the rotational axis of the spin [42]. 
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This motion is called precession and its frequency is referred to as Larmor frequency �0.
�� � �����
2.1.2  Magnetic Resonance 
In the presence of a static magnetic field, which produces spin polarization, a radio frequency 
field of a proper frequency can induce a transition of a nucleus from the lower energy level to 
the higher energy state. This transition, also referred to as “spin flip”, requires absorption of 
radio frequency energy. The absorption of energy, called “resonance”, can only occur at a 
resonance frequency equal to the Larmor frequency �0. The resonance frequency is directly 
proportional to the field strength of the external magnetic field B0. The spectrometer used in 
the present study operated at the field strength of 14.1 Tesla, providing a resonance frequency 
of 600 MHz. 
During an NMR experiment, the excess spins in an orientation parallel to the external 
magnetic field give rise to a microscopic magnetization. This magnetization is flipped into the 
x-y-plane and due to the rotation, caused by the Larmor frequency, induces a voltage in the 
receiver coil, which can then be read off as the NMR signal. This produces a radio frequency 
signal that is measured in NMR spectroscopy. During the relaxation process, the transverse 
magnetization relaxes back into equilibrium, leading to the characteristic decreasing voltage 
in the receiver coil, called free induction decay (FID). Subsequently, a Fourier transformation 
produces the NMR spectrum that can then be used for qualitative or quantitative evaluation. 
2.1.3  Chemical Shift and J- coupling 
The use of NMR spectroscopy in organic chemistry is based on the close relationship between 
information that can be obtained through NMR spectra and the molecular structures of the 
chemical compounds. Two quantities are measurable in NMR spectroscopy, the “chemical 
shift” and “J coupling”. These parameters explain a characteristic change of resonance 
frequency of a chemical compound that is the basis for molecular structure analysis. Each 
nuclear isotope in a homogenous magnetic field would be expected to provide a single narrow 
peak at the Larmor frequency of that field. However, the Larmor frequency of a given nucleus 
is influenced by the electronic structure of its atomic environment. Electrons surrounding the 
proton in a covalent bond are magnetic. They, therefore, in response to the external magnetic 
field, generate a secondary field which shields the nucleus from the external field. Thus, 
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different magnetically inequivalent nuclear spins resonate at slightly different field strengths. 
This phenomenon is called chemical shift. Chemical shifts are very small compared to the 
actual field strength of the external magnetic field and are commonly referred to as parts per 
million (ppm). They are displayed in relative units, using a reference compound.  Most 
commonly, tetramethylsilane (TMS) serves as reference compound; its chemical shift equals 
zero by definition. TMS spins have a very strong shielding. Because of that, the vast majority 
of chemical compounds have a positive chemical shift when referenced to TMS.  
In Figure 6, the structure formula and an exemplary 1H NMR spectrum of lactate are 
displayed. Lactate is one of the most common and best analyzed metabolites present in the 
spectrum of PCa, mainly because of its distinguished peak pattern. Its accumulation is due to 
increased metabolism in cancer and is a sign of high malignancy. The electro-negative 
oxygen-atoms in the chemical compound of lactate exert a shielding and are the origin of the 
chemical shift in this molecule. The methyl compound (–CH3) is shielded more than the 
methin compound (-CH), causing a lower Larmor frequency and resonance at 1.33 ppm as 
opposed to 4.1 ppm. The different chemical shifts and Larmor frequencies cause the distinct 
peak pattern of lactate with a peak at 4.1 ppm and a 3- fold higher peak at 1.33 ppm. 
Figure 6: Molecular structure (A) and 
1
H NMR spectrum (B) of the metabolite lactate: the methyl 
compound (-CH3) is shielded more than the methin compound (-CH), causing a distinct peak 
pattern with a peak at 4.1 ppm and a 3- fold higher peak around 1.33 ppm [43]. 
J coupling or spin-spin coupling describes the phenomenon that single peaks are split into 
multiple peaks (multiplets) because of small interactions, ‘coupling’, through the chemical 
bonds between neighboring protons in a chemical compound. A proton spin in a proton group 
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in the chemical compound can have two possible orientations, either aligned or opposed to an 
applied magnetic field. Opposed spins have the effect of altering the magnetic field 
experienced by the neighboring protons. Therefore, a single peak is split into two peaks by 
one single coupling proton. In case of a greater number of coupled equivalent protons in a 
neighboring group, the variety of spin direction combinations increases. Hence, two coupling 
protons result in a triplet peak with an intensity ratio of 1:2:1, as there is only one spin 
combination of the two spins causing an upfield and a downfield shift, whereas there are two 
ways of generating the inner peak, characterized by no shift. Coupling to three protons results 
in eight possible spin combinations and produces a quartet split with an intensity ratio of 
1:3:3:1. In general, if a nuclear spin is coupled to n equivalent spins of one-half, its peak is 
split into an (n+1)- fold multiplet with an amplitude ratio proportional to the binomial 
coefficients nCr (r = 0, 1, …, n). The spacing between the peaks of a multiplet is always 
constant, characterized by the coupling constant J, which is independent of the applied 
magnetic field.  Therefore, a multiplet can always be recognized by its closely spaced 
chemical shift peaks. Equivalent nuclei (spins of a distinct proton group with equivalent 
binding characteristics) do not interact with each other and do not cause a splitting. Below in 
Figure 7, the characteristic structure of the lactate NMR spectrum is demonstrated. The proton 
of the methin-compound (-CH) is coupling to the methyl-compound (-CH3). It therefore splits 
into a quartet peak with an amplitude ratio of 1:3:3:1. The lactate methyl peak is split into a 
double peak by coupling to the methin compounds. 
Figure 7: Illustration of scalar coupling of NMR lines of lactate: (A) Splitting of the methin peak 
into a quartet with intensity ratio of 1:3:3:1 by coupling with the methyl group, (B) splitting of the 
methyl peak into a doublet with an intensity ratio of 1:1 (B) [43]. 
���
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2.2  Nuclear Magnetic Resonance Spectroscopy 
In nuclear magnetic resonance (NMR) spectroscopy, radio-frequency signals emitted by spins 
that are transitioning back to their original low-energy state are being displayed in a spectrum, 
as a function of their resonance frequency. Peak integrals in the spectrum correlate with the 
number of spins in the sample giving rise to this specific signal. Therefore, quantitative 
information about the chemical compounds present in a scanned sample can be obtained 
through NMR spectroscopy. High field NMR spectrometers have been shown to provide 
spectra with a high resolution and a low signal-to-noise-ratio. 
2.2.1  Magic Angle Spinning and 
1
H HRMAS NMR Spectroscopy 
“Magic Angle Spinning” (MAS) was first described in 1958 by E. Andrew, A. Bradbury, and 
R. Eades [44] and independently in 1959 by I. J. Lowe [45], and is a technique that was 
originally developed for solid-state NMR spectroscopy studies. 
In NMR of liquid samples, anisotropic interactions between nuclei are usually averaged out 
by the isotropic rotational diffusion. In more solid-like structures, such as biological tissues, 
the molecules undergo motions in restricted geometries, which give rise to anisotropic effects, 
such as dipolar couplings, quadrupolar interactions or chemical shift anisotropy. These effects 
result in spectral line broadening, that renders a clear distinction of different metabolites 
impossible.  
By mechanically rotating (spinning) the sample at an angle of � =54.74° with respect to the 
direction of the external magnetic field, the anisotropic interactions can be averaged to zero, 
as all anisotropic interaction Hamiltonians are scaled by the factor ½(3cos2�-1). This 
procedure mimics the fast isotropic tumbling of the molecules in solution that leads to the 
averaging of all anisotropic interactions. The angle of � =54.74° is called the “magic angle”. 
Rapid spinning of a sample at the magic angle can reduce the spectral line-broadening and 
results in highly resolved spectra (Figure 8). This spectroscopy method is therefore named 
“1H High Resolution Magic Angle Spinning Nuclear Magnetic Resonance Spectroscopy”  
(1H HRMAS MRS). 
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Figure 8: Principle of magic-angle spinning: The sample (blue) is rotated with high frequency 
within the external magnetic field (B0). The axis of rotation is tilted by the magic angle �m with 
respect to the direction of B0[42].
In 1996, Cheng et al. reported the use of 1H HRMAS MRS on intact human tissue samples for 
the first time [34]. They were able to show that using this method on biological tissue 
samples, it is possible to omit the destruction of tissue architecture, while at the same time 
spectral line-broadening can be minimized and spectral resolution can be increased [46]. 
Subsequent histopathological analysis can be performed following an 1H HRMAS MRS 
experiment to investigate correlations between these biochemical spectra and the pathology of 
a sample [47, 48]. Since 1997, multiple studies have been performed in order to improve the 
technique of 1H HRMAS MRS and evaluate its clinical applicability. This method has been 
shown to be highly reproducible, with the potential to be computer- automated [34, 35, 47, 
49,50]. 
2.2.2  MAS Spinning Rates and Spinning Side Bands 
Fast spinning at the magic angle is necessary to average out anisotropic effects and decrease 
spectral line broadening. Spinning rates for 1H HRMAS MRS on biological tissues are 
commonly around 1 kHz or higher. With the smallest rotors, a spinning rate up to 70kHz and 
higher is possible. However, fast spinning increases the risk of destructing tissue architecture. 
To preserve a better tissue quality for subsequent pathological evaluation, a reduction of 
sample spinning rates has proven to be useful. Spinning rates of 600Hz or 700Hz have been 
shown to minimize the destruction of tissue architecture through HRMAS centrifugation 
while at the same time providing equally good spectral information as higher spinning rates 
[37].
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At slow-rate spinning, single pulse spectra are dominated by a large water peak and its 
“spinning sidebands”, originating from the oriented water in the tissue. Spinning sidebands 
describe signals that appear as additional peaks in the spectrum on either side of a large 
genuine peak. They are caused by the chemical shift anisotropy and appear at distances to the 
genuine peak that are multiples of the spinning frequency [51]. In biological tissues, residual 
anisotropic interactions are very weak and spinning side bands are typically not observed. 
However, if present, special rotor-synchronized suppression methods, like the TOSS pulse 
sequence protocol, can be used to effectively suppress spinning sidebands. Also, by applying 
a simple minimum function (Min(A, B), described below) on two spectra acquired at different 
but close spinning rates ( for example 600Hz and 700Hz), spinning-sideband-free spectra can 
be produced [52]. 
In biological tissues, water is normally three orders of magnitude more abundant than other 
metabolites. In order to recover metabolites that overlap the strong baseline of the water 
resonance, suppression of the water signal is necessary during the acquisition of NMR 
spectra. The elimination of the water signal without losing other resonances is challenging 
[53]. Various water suppression protocols have been suggested, among them a DANTE (delay 
alternating with nutation for tailored excitation) pulse sequence protocol.  
While preventing tissue damage by HRMAS centrifugation, slow-rate spinning has been 
shown to be sensitive enough for the purpose of disease diagnosis.  
�
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2. 3  Metabolomics, Metabolite Profiles and Clinical Utility 
Metabolomics has been  defined as the study of the metabolome, which represents “the 
complete set of metabolites or low-molecular-weight intermediates, which are context 
dependent, varying according to the physiological, developmental or pathological state of the 
cell, tissue, organ or organism” [54]. This evolving field of science uses fundamental 
analytical techniques to study the global variation of metabolites by examining the underlying 
biochemistry of cellular processes. It profiles the metabolites present at the very moment of 
analysis. Metabolites can best be described as molecules that are products, reactants, 
intermediates or waste products generated during the execution of signals that a cell is 
receiving. Thus, each cellular process has its own metabolic signature and the analysis of 
metabolite concentrations can be used to create a metabolic profile that may function as a 
biomarker for the process [21]. Different techniques can be used to explore the metabolome 
and create metabolic profiles, including Mass Spectrometry (MS) and NMR spectroscopy. 
While MS is a highly sensitive method that rapidly provides extensive metabolic information, 
it requires extensive sample preparation (separation, extraction). NMR, on the other hand, has 
the ability to rapidly identify and quantify the majority of metabolites present in a sample, 
with only minimal sample preparation. Due to the characteristic chemical shift of a given 
chemical compound, the spectral peak pattern is uniquely characteristic for that metabolite, 
making it possible to identify and quantify the metabolites present in a sample. The metabolite 
concentration can be determined by measuring the area under the associated peaks. Certain 
metabolites play a crucial role in the characterization of malignant transformations in the 
prostate and can be assessed by using MR spectroscopy. For instance, in healthy prostate 
tissue and the corresponding fluid, high levels of citrate (Figure 9, concentration  
8,000-15,000 nmol/g, compared to 150- 450 nmol/g in other soft tissues). In malignant 
prostate tissue, a pathological citrate oxidation can be found, resulting in a decrease of citrate 
levels (1,000-2,000 nmol/g) in the organ. 
Figure 9: Molecular structure and chemical formula of the metabolite citrate [55]. 
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concentrations. The ratio most relevant in the clinical application of MRS of the prostate is 
choline + creatine to citrate ( (Cho+Cr)/Cit ). It has been shown to correlate with the Gleason 
score and can therefore be used for in vivo clinical classification of prostate samples [21, 60]. 
A ratio ranging two standard deviations above average is classified as suspicious and a ratio 
of three standard deviations as very suspicious for malignant transformation [65]. Other 
metabolite ratios can be used in the differentiation of cancerous versus non-cancerous tissue.  
In malignant prostate tissue, the ratios of total choline to citrate ( tCho/Cit ), choline to 
creatine ( Cho/Cr ), glycerophosphocholine plus phosphocholine to creatine 
( (GPC+PC)/Cr ) and lactate to alanine ( Lac/Ala ) have been shown to be significantly 
increased, while the ratio of citrate to creatine ( Cit/Cr ) has been found significantly 
decreased, compared to benign tissue [60]. A significant correlation with the Gleason score 
has been demonstrated for certain metabolite ratios, including choline to creatine ( Cho/Cr ), 
choline to citrate( Cho/Cit ), citrate to creatine ( Cit/Cr ) and glycerophosphocholine plus 
phosphocholine to creatine ( (GPC+PC)/Cr ).  
Table 1 summarizes the observed changes in single metabolites (1a) and metabolite ratios (1b) 
in benign versus malignant human prostate tissue. 
Table 1a:  Observed changes in single metabolite concentrations in malignant versus benign 
human prostate tissue samples [66].
Metabolite Change Reference 
Lactate Increase [60] 
Alanine Increase [60] 
Citrate Decrease [59] 
Choline Increase [59] 
Phosphocholine Increase [59, 62] 
Glycerophosphocholine Increase [59, 62] 
Ethanolamine Decrease [62] 
Phosphoethanolamine Increase [62] 
Glycerophosphoethanolamine Increase [62] 
Polyamines Decrease [59] 
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Table 1b:  Observed changes in metabolite ratios in malignant versus benign human prostate 
tissue samples [66]. 
Metabolite Ratio Change Reference 
Choline / Creatine Increase [60] 
Lactate / Alanine Increase [60] 
(Glycerophosphocholine + Phosphocholine) / Creatine Increase [60] 
Citrate / Creatine Decrease [60] 
(Choline + creatine) / Citrate Decrease [60] 
Phosphocholine / Glycerophosphocholine Increase [62] 
Phosphocholine / Phosphoethanolamine Increase [62] 
Phosphoethanolamine / Ethanolamine Increase [62] 
Glycerophosphoethanolamine / Ethanolamine Increase [62] 
To make MR spectroscopy results more applicable to clinical use, metabolite profiles, also 
referred to as metabolomics profiles, were created. Instead of observing only the change in a 
single metabolite caused by malignant processes, large ensembles of metabolites were 
analyzed [50, 62, 67, 68]��The resulting profiles of PCa have the potential to be effective tools 
in the in vivo diagnosis of cancer of the prostate. The diagnostic utility of PCa metabolomics 
profiles has been studied extensively in the past years using 1H HRMAS MRS. Spectroscopy 
results obtained from prostatectomy tissue samples of biopsy-proven PCa patients were 
evaluated using principle component analysis and correlated to the results of subsequent 
histopathology. The resulting metabolite profiles of PCa appear to be sensitive in 
differentiating benign from malignant tissue and furthermore, to correlate with patients serum 
PSA-level. Previous results indicated that prostate metabolic profiles may reflect cancer status 
even more sensitively than currently available histopathological parameters [50]. 
Besides studying prostate cancer, other malignant transformations have been investigated 
successfully, using 1H HRMAS MRS. Metabolite spectra have been obtained from samples of 
human glioblastoma multiforme [47] and other brain tumor species [49], human breast ductal 
carcinomas [69], Alzheimer’s disease [70] or pediatric brain tumors [71]. Current research 
efforts aim at creating and improving metabolomics profiles of different malignant 
transformations and evaluating their diagnostic utility for future in vivo use.  
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3 Scientific Background II: Immunohistochemistry of Prostate Cancer 
Immunohistochemistry (IHC) refers to a scientific method that is based on the principle of 
antibodies binding specifically to antigens in biological tissues [72]. IHC staining is widely 
used in medical research to detect and diagnose biomarkers, specific proteins or abnormal 
cells (for example in malignant transformations). An antibody-antigen interaction is 
visualized by the conjugation of the antibody to an enzyme (like peroxidase or phosphatase) 
that catalyzes a color-producing reaction or a fluorophore (most commonly fluorescin or 
rhodamine) that produces immunofluorescence. For antibodies, both monoclonal and 
polyclonal antibodies can be used. In contrast to polyclonal antibodies, monoclonal show 
specificity for a single epitope and are therefore more valuable to target a specific antigen. 
Antibodies can be directly labeled with an IHC reporter that is able to detect the target with an 
enzyme- or chromophore- reaction. This direct IHC method is simple and rapid but shows a 
low sensitivity. To improve sensitivity, an indirect method can be used, where an unlabeled 
primary antibody binds to the target antigen and a labeled secondary antibody is used to detect 
the primary antibody. Due to the binding of several secondary antibodies to each primary 
antibody, signal amplification can be achieved and sensitivity improved. To further signal 
amplification, secondary antibodies are often conjugated with biotin molecules that can 
recruit avidin-, streptavidin- or neutravidin proteinbound complexes. IHC reporter molecules 
are chromophore or fluorophore enzyme labels that react with the substrate to produce a color 
(chromogenic reaction) or fluorescence. Alkaline phosphatase and horseradish peroxidase are 
the most commonly used labels in chromogenic IHC. A wide range of substrates is available 
for different color reactions. Most often, 3,3`-Diaminobenzidine (DAB) is used to produce a 
brown color, but other substrates like 5-Bromo-4-chloro-3-indolyl phosphate (BCIP) and nitro 
blue tetrazolium chloride (NBT), producing a dark blue or purple color, are available as well. 
As immunological reactions are highly susceptible to external influences, IHC requires a 
careful sample preparation. Tissue samples are commonly micro-sectioned, formalin-fixed 
and embedded in paraffin. In order to make epitopes available for antibody binding, several 
steps like deparaffinization and antigen retrieval have to be carried out. To ensure a good 
staining quality, endogenous biotins or enzymes need to be blocked or quenched prior to 
staining. Nonspecific binding that results in background stain and can mask the detection of 
target antigens can be reduced by incubating the samples with a buffer that blocks the reactive 
sites. After all steps of the IHC method have been carried out, a counterstain can be applied to 
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provide a contrast that helps to enhance the detection of the primary stain. Common 
counterstains include Hematoxylin, 4´,6-diamidino-2-phenylindole (DAPI) or Methyl Green. 
Immunohistochemical methods have been proven useful in the diagnosis of different 
malignant transformations, including prostate cancer [38, 39,73] and have been increasingly 
incorporated in basic diagnosis. 
  
A cytoplasmic protein involved in the beta-oxidation of branched-chain fatty acids, P504S, 
also known as AMACR (alpha-methylacyl-CoA racemase), shows high expression in prostate 
cancer and a modest expression in benign prostate tissue. It can therefore be used as an 
immunomarker to differentiate between cancerous and non-cancerous glands [74-76]. 
Another protein, CK903, also known as 34-beta-E12 (high molecular weight cytokeratin), is 
highly expressed in the cytoplasm of basal cells of healthy prostate glands, whereas it cannot 
be found in cancerous tissue.  It functions as a marker of benign prostate tissue [77]. The 
tumor suppressor protein p63 is a basal cell marker that can be used to stain nuclei of benign 
prostate gland epithelium. p63 belongs to the same family of tumor suppressor proteins like 
p53 and p73 and has been suspected to be the original family member, with p53 and p73 
being  derived from it [78]. p63 gene encodes for 2 protein isoforms, one of which (TAp63) 
plays an important role in apoptotic function [79]. With the help of p63-antibodies it is 
possible to differentiate between prostate adenocarcinoma and benign prostate tissue, as 
malignant glands do not have basal cells that could be stained. Also, p63 immunostaining can 
be used to differentiate between urothelial cancer (high expression) and PCa (no expression) 
in cases where a clinical differentiation seems difficult [80]. By combining IHC stainings of 
P504S with those of CK903 and p63, cancerous prostate samples can be differentiated from 
both normal prostate tissue and benign lesions. While P504S has a positive expression in both 
PCa and Prostate Intraepithelial Neoplasia (PIN), the stainings for both CK903 and p63 are 
negative in PCa and positive in PIN, making a differentiation between cancer and PIN 
possible. Benign prostate hyperplasia (BPH) is a benign transformation of the prostate. BPH 
is a relatively common disease in older men and is not classified as precancerous lesion. 
While non-cancerous prostate tissue stains positive for CK903 and p63, BPH does not [81]. 
Therefore, IHC is a useful tool for the differentiation of cancerous from non-cancerous 
conditions, but also malignant from benign transformations or preliminary stages.  
Besides using the mentioned immunomarkers separately on suspicious prostate tissue, they 
can also be combined as a triple-cocktail-staining with a single- or double chromogen 
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reaction, making it possible to obtain immunohistochemical information from the very same 
tissue [73, 82]. 
Compared to conventional histopathologic examinations, IHC has several advantages in the 
diagnosis of PCa. Conventional histopathologic analysis of suspicious tissue after prostate 
needle biopsy or prostatectomy is commonly carried out using a Hematoxylin & Eosin 
staining procedure. Subsequently, the stained tissue slides have to be analyzed by a 
pathologist with fundamental knowledge on prostate tissue pathology. In contrast, IHC 
provides objective pathology results, based on the fact that staining occurs only in tissue that 
expressed the targeted antigens. Using the immunomarkers P504S (AMACR), CK903 and 
p63, it is possible to obtain an objective differentiation of tissue pathology in suspicious 
prostate tissue. The chromogenic reaction that is part of the visualization in IHC also yields 
the opportunity for a computer automated evaluation. DAB produces a dark brown color that 
provides a good enough contrast between benign and malignant tissue. A specifically 
designed computer program could be used to measure cancerous and non-cancerous tissue 
distribution in a sample through the detection of dark versus light tissue areas. IHC therefore 
has the potential to allow objective and fast evaluation of large numbers of tissue samples, 
minimizing intra- and inter-observer- variability. 
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4 Aims of the Study 
Current methods for prostate cancer diagnosis are not satisfying and overdiagnosis and 
overtreatment are very common, due to the insufficiency of state-of-the-art diagnostic tools to 
accurately distinguish between highly aggressive and malignant cancers and more indolent 
cases. Novel, observer-independent and quantitative diagnostic methods for PCa are urgently 
needed. This study aims to establish a novel approach for identification of PCa biomarkers, by 
quantification of metabolomic profiles measured from prostate tissue by 1H HRMAS MRS. 
It has been demonstrated that 1H HRMAS MRS does not destroy the tissue architecture of a 
sample, thus allowing for unbiased subsequent histopathological evaluation of a scanned 
tissue piece [16, 49]. In previous studies of prostate cancer metabolomics, conventional 
histopathology was commonly used as reference standard [16], due to its facile utility and 
broad clinical applicability. Immunohistochemistry, in contrast, presents a more accurate and 
objective diagnostical method than conventional histopathology, and yields the potential to be 
computer automated. Therefore, this study aims to explore the potential of three prostate 
immunomarkers- P504S (Alpha-Methylacyl-CoA-Racemace), CK903 (high-molecular weight 
cytokeratin) and p63- as tools for quantitative analysis of immunohistochemistry performed 
on the same tissue samples. 
To achieve this aim, a quantitative IHC analysis program was developed to automatically and 
objectively determine the percentage of cancerous and benign glands in a prostate tissue 
sample. Additionally, this project aims to confirm the validity of the presented approach by 
using a conventional histopathological evaluation and a quantitative IHC analysis performed 
by an experienced pathologist. This study aims to use these quantitative measures of tissue 
pathology obtained from IHC to identify PCa biomarkers in a metabolomic profile measured 
with 1H HRMAS MRS in the same sample. For that, correlations of spectral intensities with 
the results of quantitative IHC analysis will be examined.  
In an attempt to explore the stability and utility of the proposed immunomarkers for use 
following 1H HRMAS MRS, the presented project aims to compare the quality and 
evaluability of immunostainings of tissue sections that have been subjected to 1H HRMAS 
MRS to samples from the same prostate that have not undergone spectroscopic procedures, in 
a subset of the sample cohort. 
To further explore the potential of our novel approach, this study aims to investigate the 
utility of it to identify metabolomic biomarkers of PCa recurrence. For that, patient outcomes 
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and recurrence five years after initial diagnosis will be obtained and correlated to the results 
of  1H HRMAS MRS to identify metabolomic markers of recurrence in the dataset. 
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5 Material and Methods 
Tissue acquisition, medical record review and all experiments performed in this study were 
approved by the Institutional Review Board (IRB) of the Massachusetts General Hospital 
(MGH) and in accordance with the Health Insurance Portability and Accountability Act 
(HIPAA). 
5.1  Prostate Tissue Samples and Patient Demographics 
Human prostate tissue specimens were prospectively collected from 51 biopsy-proven PCa 
patients who underwent prostatectomy surgery at the Department of Urology at the MGH in 
Boston, between January of 2007 and December of 2008. The tissue samples were collected 
from the operating suite, instantly frozen and stored at a temperature of -80°Celsius prior to 
the experiments. 
The patient medical records were reviewed to determine important demographic information, 
including: patient’s age at surgery, pre-operative PSA-levels, final histopathological 
diagnosis, including GLEASON grades, and adjuvant treatment, if administered (defined as 
any additional treatment in a time-period of less than 6 months before or after surgery).  
5.2  
1
H HRMAS NMR Spectroscopy 
Spectroscopy measurements were carried out on an AVANCE 600MR spectrometer 
(BRUKER Biospin, Billerica, MA) operating at 600.13 MHz (14.1T). A 4-mm zirconia rotor 
was used with Kel-F inserts to create a 12 µl-spherical space that confined the tissue to the 
center of the receiving coil. A small silicone rubber sample, permanently fixed inside one of 
the Kel-F spacers, functioned as external reference standard for frequency reference (0.06ppm 
from TMS) and concentration quantification (Figure 12). 
���
�
Figure 12: BRUKER Biospin
Biomedical Imaging”, Massachu
5.2.1  Sample Preparation
The sample preparation was p
the spectrometer. The prostate
(-80 degrees Celsius).  To p
specimens were stored on dr
(approximately 10mg) was cu
carefully placed into the rotor
micro weight scale. Dependin
D2O were added for 
2H field l
marked at the bottom with a pe
5.2.2   Spectroscopy Scan 
After adjusting the magic angl
tissue preservation, with the re
phase adjustments as well as s
was regulated by a MAS contr
spinning frequencies of 600H
AVANCE III 600MHz spectrometer at the “M
setts General Hospital / Harvard Medical Scho
erformed at room temperature in a preparati
 tissue samples were collected from the stora
revent tissue destruction during the prepa
y ice at all times during handling. A sm
t from each sample, using a scalpel with a 
. The weight of the sample in the rotor was
g on the total weight of the tissue piece, bet
ocking. The rotor was carefully closed with 
rmanent marker, and placed into the probe. 
e, MR spectra were recorded at a temperatu
sonance frequency centered on the water re
himming were performed if necessary. The 
olling interface. Water suppressed spectra w
z and 700Hz. A rotor synchronized DANTE
artinos Center for 
ol, Boston 
on area adjacent to 
ge freezer 
ration process, the 
all piece of tissue
blade size 10, and 
 measured using a 
ween 2 and 8µl of 
a screw and a cap, 
re of 4°C for better 
sonance. Lock and 
rotor-spinning rate 
ere recorded using 
 (delay alternating 
���
�
with nutation for tailored excitation) pulse sequence (1000 DANTE pulses of 1.5µs, 8.4° flip 
angle) [37] for water suppression was used in combination with a Carr-Purcell-Meiboom-Gill 
(CPMG) pulse sequence at short TE (30ms). A repetition time of 5s and an average 32 
transients were used. 
The CPMG pulse starts with a 90° pulse which flips the magnetization in the x-y-plane. Then, 
during the decay that follows, some spins slow down due to lower local field strength, while 
others speed up. T2* decay refers to an exponential decrease in signal strength compared to 
T2 decay, due to inhomogeneity of the magnet. In the CPMG pulse sequence, a series of 180° 
pulses is applied, which make it possible to refocus the T2* signal and remove inhomogeneity 
effects in order to correct pulse-accuracy errors (Figure 13).
Figure 13: Carr-Purcell-Meiboom-Gill pulse sequence (echo train acquisition): after an initial 90° 
pulse, multiple 180°pulses are applied to refocus inhomogenous line broadening of the nuclear 
spins. This technique is used to self-correct accuracy errors in T2- (spin-spin relaxation) weighted 
imaging [83]. 
5.2.3  Data Processing 
NMR data (BRUKER Biospin 14.1T raw data) was manually processed offline using the 
commercial software NUTS (Acorn NMR Inc., Livermore, CA). All free induction decays 
were subjected to 1Hz apodization before Fourier transformation, followed by baseline 
correction and phase adjustment of both zero and first order.  A typical dataset before and 
after Fourier transformation is illustrated in Figure 14. 
���
�
B 
Figure 14: Typical 
1
H time (A) and frequency (B) domain data: FID before Fourier transformation 
(A, x: time in sec, y: signal intensities) and data after Fourier transformation (B, x: chemical shift 
in ppm, y: signal intensities) 
Spectral resonance intensities used for this study represented integrals of curve fittings of 
either 600 or 700 Hz HRMAS spectra. Spectra at both frequencies were obtained in order to 
eliminate spinning sidebands (SSB) which appear at different regions in 600 and 700 Hz 
spectra. Usually, quantification of NMR metabolites by spectral modeling is conducted 
assuming an ideal Lorentzian or Gaussian lineshape. However, in reality, experimental 
A 
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lineshape fit neither of them perfectly. In order to minimize systematic fitting errors, mixed 
Lorentzian-Gaussian line shapes (Voigt lineshapes, [84]) were used in this study (Figure 15).  
Figure 15: Curve fitting process in NUTS: Peaks are manually picked by the user, individual 
integrals are calculated (green lines, A) and multiple iterations are carried out, in order to produce 
an optimized curve fit (red line, B). Blue line: original spectrum. 
In order to produce SSB- free spectra, spectral intensities acquired at 600Hz and intensities 
recorded at 700Hz from the same sample were subjected to a simple processing scheme called 
Min (A,B): By calculating the minimum values from both spectra for the entire range of 
A 
B 
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interest, SSB could be eliminated, as they occurred at different intervals from the water peak 
[52]. The spectra were referenced using the lactate double peak at 1.34 and 1.32 ppm. Spectral 
intensities were then measured in 36 regions of interest, known to represent characteristic 
regions of PCa metabolites, as described previously (the most relevant are displayed in Table 
2, [50]). Final spectral intensities were calculated from relative intensities normalized by the 
overall intensity of the spectral region between 0.5 and 4.5 ppm from the spectrum recorded at 
600Hz [37]. 
Table 2: Spectral regions of interest for prostate cancer metabolites [50].
Spectral region in ppm Metabolite(s)
4.38 N-acteylaspartate 
4.09 Lactate 
3.75 L-glutamine 
3.74 L-glutamic acid 
3.605 Glycerophosphocholine 
3.52 Myo-inositol 
3.42 Taurine 
3.22 Phosphocholine 
3.18 Choline 
3.05 – 3.14 Spermine 
3.02 Creatine / Phosphocreatine 
2.52 -  2.71 (Sodium-) Citrate 
1.92 Acetate 
1.46 Alanine 
1.32 /1.34 Lactate 
0.9 Lipids 
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5.3  Immunohistochemistry 
5.3.1  Immunohistochemistry Material and Equipment 
The immunomarkers P504S, CK903 and p63 were chosen for this study, as their specificity 
and utility as well as their clinical applicability have been demonstrated multiple times in the 
literature [73, 82, 85]. As primary antibodies, rabbit monoclonal anti-human AMACR 
(P504S), mouse monoclonal anti-human CK903 and mouse monoclonal anti-human p63 were 
used. Biotinylated anti-rabbit IgG and biotinylated anti-mouse IgG were applied as secondary 
antibodies. For the visualization of the immune reaction, a single color reaction was 
performed, using 3,3`-Diaminobenzidine (DAB). DAB was chosen for visualization, because 
of its characteristic dark brown color, which facilitates qualitative evaluation and furthermore, 
yields the potential for computer- automated quantitative evaluation. A summary of all 
materials and chemicals used for IHC can be found in Table 3. 
5.3.2.  Immunohistochemistry Protocol 
An IHC staining protocol was established in our laboratory according to antibody/reagent 
specifications. Effectiveness and specificity experiments were carried out using confirmed 
PCa tissue as positive control. Different incubation times and antibody dilutions were tested 
to identify the best possible staining conditions. The following IHC protocol illustrates the 
optimized algorithm for the immunostaining experiments in this study.  
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Table 3: IHC Antibodies, Reagents and Equipment* 
Antibodies Chemicals / Reagents Materials /Equipment 
Rabbit monoclonal anti-human 
AMACR antibody, 1:50 (DAKO) 
Formalin (FS) 
Microtome 
(Leica RM2235) 
Mouse monoclonal anti-human 
CK903 antibody,1:50 (DAKO) 
Xylene (FS) 
Paraffin embedding station 
(Leica) 
Mouse monoclonal anti-human 
p63 antibody, 1:50 (DAKO) 
Ethanol 100% / 95% / 75% 
(FS) 
Barrier slides (Biogenics) 
Secondary biotinylated anti-rabbit 
IgG, 1:50 (FS) 
Paraffin (FS) Baking oven (GE) 
Secondary biotinylated anti-
mouse IgG, 1:50 (FS)
Deionized H2O 
Microwave with temperature 
probe, 800W (GE)
Phosphate buffered saline 
(PBS), (FS) 
Beakers (FS)
TRIS 7 EDTA buffer, pH 9.0, 
10mM, 1mM (FS) 
Pipetters + pipette tips (1000µl, 
200µl, 20µl) (Gilson, VWR)  
Methanol (FS) Kim Wipes (KimTech) 
Hydrogenperoxide (H2O2), 
(FS) 
Dry Ice and Ice 
Protein Block (DAKO) Humid Chambers (FS) 
Avidin / Biotin / Peroxidase 
Complex (Vectastain) 
Permanent mounting media 
(FS) 
Diaminobenzidine 3’3 tablets 
(Sigma Aldrich) 
Slide covers (FS) 
Methyl  Green (FS) 
Hematoxylin (FS) 
Eosin (FS) 
* FS... purchased from Thermo Fisher Scientific (Hampton, NH)
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5.3.2.1  Sample Preparation 
After completion of NMR spectroscopy, the prostate tissue samples were removed from the 
rotor, fixed in a formalin bath overnight and embedded in paraffin. Small tissue sections 
(5µm) were cut using a microtome and transferred instantly on barrier glass slides. 
The slides had to be baked at a temperature of 60°C for 2 hours, in order to insure tissue 
adherence. They were then deparaffinized and rehydrated according to the following steps: 
- Xylene     3 x 5 min 
- Ethanol 100%     2 x 5 min 
- Ethanol 95%     1 x 5 min 
- Ethanol 70%     1 x 5 min 
- Deionized H2O    2 x 5 min 
To ensure hydration and prevent tissue sections from drying out, slides were either incubated 
with a target solution or kept in a buffer solution at all times. Three adjacent slides were used 
for immunostaining with the designated primary antibodies. A fourth adjacent slide was left 
for staining with Hematoxylin & Eosin (see section Qualitative Histopathology). 
5. 3.2.2 Antigen Retrieval, Quenching of Endogenous Peroxidases and Protein Block 
To improve the demonstration of antigens, an antigen retrieval step was required prior to the 
application of the primary antibodies. During formalin-fixation, methylene bridges are formed 
that cross-link proteins, therefore masking antigenic sites. Antigen retrieval, a method 
discovered in the early 1990`s [86] is a non-enzymatic pretreatment to break down these 
protein-cross links, thereby uncovering hidden epitopes [87, 88]. The technique most 
commonly used is called “Heat Induced Epitope Retrieval (HIER)”.  Formalin-fixed, paraffin-
embedded tissue slides are heated in a specific antigen retrieval solution for a designated time. 
Microwave, steamer, autoclave or water bath serve as suitable heating devices. Citrate buffer 
(pH 6.0) and TRIS/EDTA (pH 9.0) or EDTA (pH 8.0) buffer solutions are suitable for most 
antigens [89]. An alternative approach for unmasking antigenic sites is “Proteolytic Induced 
Epitope Retrieval (PIER)” which uses enzyme digestion. Effective reagents include proteinase 
K, trypsin, chymotrypsin, pepsin and other proteases. The enzymatic method tends to be much 
gentler, but sometimes may destroy tissue morphology [90]. 
Heat induced epitope retrieval using TRIS/EDTA buffer solution (pH 9.0,10mM/1mM) for 
P504S (AMACR) and citrate buffer (pH 6.0, 0.1M) for CK903 and p63 respectively were 
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identified as suitable antigen retrieval solutions for this study in preliminary experiments.  
Deparaffinized and rehydrated tissue slides had to be immersed into the determined retrieval 
solutions and heated in a commercial microwave (800W, 199°C) for 30 minutes. Afterwards, 
the slides had to cool down in a tap water bath for 15 minutes.  
Endogenous peroxidase activity in cells or tissue sections used for IHC may cause high, non-
specific background staining, due to catalyzation of chromogenic or chemiluminescent 
substrates. To improve the staining quality in this study, the non-specific background staining 
was reduced by quenching (irreversible inactivation) of endogenous peroxidases. For that, 
tissue slides were immersed into deionized H2O and PBS for 5 minutes each. Then, 3% H2O2
in methanol was applied to sections for 10 minutes. Slides were washed in deionized H2O 
again for 5 minutes. 
To enhance the detection of a target antigen in IHC procedures, an Avidin-Biotin-Complex 
(ABC) has been proven useful. Biotin, a coenzyme in many biological reactions, has a strong 
binding affinity with avidin and can thus be conjugated to antibodies for labeling purposes.  
However, free or labeled avidin not only binds to conjugated biotin but also to endogenous 
biotin, thus causing high background staining in tissues rich in endogenous biotin [91]. 
Therefore, a biotin block (protein block step) is necessary to ensure good staining quality. 
Protein blocking was performed using a commercially available protein block solution. As 
protein block is highly susceptible to high temperatures, the block solution had to be stored on 
ice during use and kept refrigerated. Tissue slides were incubated with the protein block 
solution in a closed humid chamber for 10 minutes at room temperature. The solution was 
shaken off after the incubation.  
5.3.2. 3 Antibody Application  
During the entire immunostaining process, all antibodies had to be stored on ice to prevent 
destruction. Three adjacent tissue slides were incubated for 75 minutes with the primary 
antibodies (200µl). Following the primary incubation, the liquids were tapped off, slides were 
rinsed and then buffer washed with PBS for 5 minutes. The next incubation step involved 
staining with biotinylated secondary antibodies for 30 minutes. The third incubation step, an 
Avidin-/Biotin-/Peroxidase- complex (ABC) was applied to all three slides for 30 minutes 
  
5.3.2.4  Visualization and Counterstain 
All tissue slides were incubated with 250µl DAB per slide for 10 minutes. For best color 
results, the DAB solution had to be prepared 24 hours prior to use and stored in a dark 
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environment, as DAB is highly light-sensitive. After DAB-application, the tissue slides were 
rinsed in deionized H2O (3x 6 dips) and counterstained with Methyl Green for 2 minutes. 
Tissue dehydrationwas performed using the following solutions: 
- Ethanol 100%     10 dips 
- Ethanol 100%     10 dips 
- Ethanol 100%     10 dips 
- Xylene     5 min 
- Xylene     5 min 
All slides were covered with permanent mounting media and slipped with cover slides while 
still wet. The slides were left to dry overnight, before they could be examined with a 
microscope. Table A1 in the Appendix section summarizes the staining process for the three 
antibodies used in this study.  
5. 3. 3  Prostate Immunomarker Stability after 
1
H HRMAS NMR Spectroscopy 
Previous studies demonstrated that 1H HRMAS MRS does not destroy the tissue architecture 
of a sample, thus allowing for unbiased subsequent histopathological evaluation of a scanned 
tissue piece [16, 49]. However, until now, the immunohistological potential and quality of 
previously scanned tissue has not been evaluated.  
In an attempt to verify that the quality and assessability of the proposed prostate 
immunomarkers, P504S, CK903 and p63, was not impacted by prior performance of  
1H HRMAS MRS, and that these markers were suitable for post-spectroscopic IHC, 28 paired 
prostate tissue sections from 14 samples were studied. Of each sample, one tissue section 
(“scanned”) was subjected to 1H HRMAS MRS scanning before subsequent performance of 
IHC, using the designated immunomarkers on three adjacent tissue slides. The second section 
of each sample (“unscanned”) was processed with IHC, without prior 1H HRMAS MRS. To 
ensure comparability of the IHC results, the “scanned” and “unscanned” sections from each 
sample were processed and immunostained simultaneously. Following the IHC procedure, the 
immunostaining quality and evaluability was judged for each tissue slide by an experienced 
pathologist using a 5-point scale (1 = poorest possible staining quality, 5 = highest possible 
staining quality). The evaluation of quality was based on staining intensity, preservation of 
tissue architecture and amount of background staining. Ultimately, the quality scores of all 
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immunostainings were compared for of each pair of matched “scanned” and” unscanned” 
slides.  
5.3.4  Qualitative IHC Analysis 
Qualitative analysis of the immunostainings was performed using an Olympus BX41 
Microscope Imaging System (Olympus American, Inc., Melville, NY). All three adjacent 
slides of each individual sample were evaluated for presence (+) or absence (-) of staining. 
The samples were then histopathologically classified (Table 4). Presence of P504S-staining 
with absence of CK903- and p63- positive glands was considered characteristic of a cancerous 
tissue sample. In contrary, absence of P504S and presence of the benign tissue markers was 
classified as non-cancerous condition. Benign Prostate Hyperplasia (BPH) is characterized by 
(mostly incomplete) loss of positivity of the benign immunomarkers and concurrent absence 
of P504S-staining. A Prostate Intraepithelial Neoplasm (PIN) can be identified by positive 
P504S-immunostaining as well as positivity for benign immunomarkers, such as CK903 and 
p63. 
All slides were centrally reviewed by a board-certified pathologist, to ensure correct 
evaluation.
Table 4: Qualitative Evaluation Diagnostic Table 
P504S CK903 p63 Diagnosis 
+ - - cancerous 
- + + non-cancerous 
- - - BPH 
+ + + PIN 
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5. 3.5  Quantitative IHC Analysis 
5.3.5.1    Quantitative IHC slide review 
The IHC tissue slides were reviewed and evaluated by a board-certified pathologist to 
quantitatively determine the presence of immunostaining for each immunomarker. Intervals of 
5% were used to judge the amount of stained glands in each cross-section.  
5.3.5.2   Computer-automated quantitative IHC analysis 
To allow for an observer-independent, objective and time-efficient quantitative IHC analysis, 
a Quantitative Immunohistochemistry Analysis Program (QIAP) was developed for this study 
with the help of software engineer Yannick Berker (University of Aachen, Germany). 
This program, based on the commercial software MATLAB (Version R2010a, Mathworks, 
Natick, MA, USA), was designed to automatically and objectively determine absolute and 
relative values of positively stained prostate gland epithelium, gland lumen area and stroma 
area in digital images of IHC tissue cross-sections. 
5.3.5.2.1  Image generation and alignment 
Digital images of IHC tissue slides were generated using an Olympus BX41 Microscope 
Imaging System (Olympus American, Inc., Melville, NY)in conjunction with the image 
analyzer MicroSuiteTM (Soft Imaging System Corporation, Lakewood, CO). A 10-fold 
magnification was used. In order to capture an entire tissue slide, multiple photographs were 
taken of each cross-section. The individual images were aligned to create a single picture of 
each slide, using the open-source panorama photo stitching and merging software HUGIN 
(Version 0.8.0,[92]). The HUGIN software accomplishes stitching by using control points in 
several overlapping photos taken from the same source to align and transform the photos, so 
that they can be blended together- creating one larger image of an entire tissue slide. The 
stitching quality of HUGIN is superior over other alignment programs, including the 
MicroSuiteTM multiple image alignment feature, as demonstrated in Figure 16. 
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Figure 19: QIAP output screen for the tissue area detection and calculation steps  
3.  Detection and calculation of epithelium points:
Visualization with DAB causes a dark brown color in positively stained gland epithelia, 
which makes it possible to detect epithelium cells that express the respective immunomarker. 
Using a brightness threshold T, all picture points with gray-values below T threshold were 
classified as positive for staining in QIAP.  A preset threshold can be adjusted interactively by 
the user via the user interface, if necessary. Threshold changes were instantly made visible by 
the program in the evaluation window, to facilitate determination of the ideal threshold. To 
obtain the most accurate results, the user needed to change the threshold to a value at which 
the tissue points that are determined to be positive by QIAP closely matched the stained 
epithelium in the original image.  
After the detection of epithelium points, a correction step was performed to reduce artifacts 
(Figure 20). Assuming that actual tissue points are interconnected, all white picture point 
clusters with a diameter of less than a certain number N of points were removed. The value of 
N is preset to 5, but could be adjusted manually by the user to increase accuracy. 
Subsequently, all detected epithelium points were added and the total epithelium value as well 
as the percentage of epithelium points in the entire picture (total epithelium value divided by 
total tissue area) was calculated and displayed in the evaluation window (Figure 20). 
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Figure 22: Interactive user interface of QIAP with adjustable parameters and results output section 
The QIAP was designed to facilitate the quantitative evaluation of immunostained tissue 
slides, by automatically and objectively determining absolute and relative values of positively 
stained prostate gland epithelium, gland lumen area and stroma area. Cancerous epithelium as 
well as benign epithelium absolute value and percentage were determined by analyzing two 
adjacent slides stained with P504S and CK903 respectively, with the program. Ultimately, a 
cancer ratio C was calculated, specified by cancer epithelium as a ratio of all epithelium 
(cancerous + benign), which could be used for further analysis. 
5.3  Quantitative histopathology 
Conventional histopathology, using Hematoxylin & Eosin (H&E) - staining, presents the gold 
standard of prostate tissue pathological analysis. For reference standardization purposes,  a 
quantitative analysis of conventional histopathology was included in this study. All tissue 
slides of each individual sample, except the three cross-sections used for IHC, were stained, 
using a standard H&E-staining procedure (Table A2, Appendix section). An experienced 
pathologist was asked to judge the percentages (in 5%- intervals) of cancerous glands, benign 
glands and stroma present in each slide. The percentages derived from each slide were 
averaged for each case, resulting in quantitative measures of cancer and benign prostate 
glands in the samples.  
���
�
For future referencing purposes, a quantitative analysis of each complete sample is not time-
efficient and manageable. Therefore, one aim of this study was to determine whether it would 
be feasible to use only one adjacent tissue slide of each case for referencing purposes. For 
that, the results of quantitative histopathology analysis of a single adjacent slide were 
compared to the averaged percentages of the corresponding case. �
�
5. 4  Identification of Prostate Cancer Metabolomic Markers
In order to identify potential metabolomic markers of prostate cancer, relative spectral 
intensities obtained from 1H HRMAS MRS had to be referenced against histopathological 
results obtained from the corresponding tissue samples. In previous studies, conventional 
histopathology was commonly used as reference standard [16], due to its broad clinical utility 
and applicability. The present study shows a novel approach to identify metabolomic markers 
of PCa, by using quantitative IHC as reference standard instead of conventional 
histopathology. 
For that, the spectral intensities of 36 regions of interest (described in 4.2.3.) of each case 
were correlated with a cancer ratio calculated from quantitative IHC of the same tissue 
sample. The cancer ratio was defined as percentage of cancer epithelium (as determined by 
QIAP) divided by the amount of all epithelia, cancerous as well as benign (by QIAP), and 
served as measure for quantitative pathology as determined by IHC. The correlation between 
cancer ratio and the corresponding spectral intensities from each sample was performed using 
a linear regression model. 
5. 5  Patient Outcomes and Recurrence Categories 
Five years after the initial diagnosis and surgery, the patient medical records were reviewed 
again retrospectively, in order to evaluate the patients’ outcome. Any adjuvant treatment 
administered was recorded as well as clinical signs of recurrence or metastasis. Furthermore, 
the date of last follow-up, PSA-levels as well as vital status at last follow-up were determined. 
Overall survival (OS) was calculated as time from initial diagnosis to death, or date of last-
follow up in survivors. Recurrence was classified into four categories, according to their 
presence und absence of PSA-elevation, clinical symptoms and metastases (Table 5). 
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Table 5: Categories of recurrence 
Category  Description
1 no evidence recurrence 
2 PSA-elevation without clinical symptoms 
3 PSA-elevation with clinical symptoms, no metastasis
4 metastatic disease 
The outcome measures ‘category of recurrence’ and OS were correlated with the spectral 
intensities in order to determine metabolomic markers of recurrence and survival.  
5.6  Statistical Analysis 
Statistical analysis was performed using the statistical software JMP 10 (SAS institute Inc., 
Cary, NC, USA) was used. 
Linear fits were used to test the correlations between quantitative histopathology and 
quantitative IHC, as well as between quantitative IHC as determined by a pathologist and as 
calculated by QIAP. In order to identify metabolomic markers of PCa from the spectral data 
and quantitative IHC, spectral intensities and cancer epithelium percentages, established by 
quantitative image analysis, were correlated with paired T-tests. Univariate analysis between 
the spectral intensities of each of the 36 regions of interest and CaE% as determined by QIAP 
was performed. Outcome measures were correlated to spectral intensities of the 36 regions. 
A p-value of less than 0.05 was considered as significant for all tests. 
�
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6 Results 
6. 1 Patient demographics 
The patient cohort was characterized by a mean age of 62.02 years (median 63, range 47-75). 
The mean pre-operative PSA was 5.79, range 0.6 -19.8, STD 2.88). The histopathological 
stage was scored as T1c in 9 cases (18.75%), T2a in 7 cases (14.58%), T2c in 20 cases 
(41.67%), T3a in 9 cases (18.75%) and T3b in 3 cases (6.25%). Only three patients (6.17%) 
had metastatic disease. The majority of patients had a low GLEASON score of 6 (23, 47.92%) 
or 7 (22, 45.83%), consistent with a relatively undifferentiated, less malignant pathology, 
while only one patient had a GLEASON grade 8 (2.08%) and two patients a GLEASON 9 (2, 
4.17%) - indicative of well differentiated, malignant pathology (Table 6). 
Table 6: Patient demographics   
Median age (range) in years  63 (47 -75) 
Mean age, SD  62.02, 6.22 
Diagnosis (%)  
T1c  9 (18.75) 
T2a  7 (14.58) 
T2c  20 (41.67) 
T3a  9 (18.75) 
T3b  3 (6.25) 
Metastasis (%)  3 (6.25) 
GLEASON score (%)  
6  23 (47.92) 
7  22 (45.83) 
8  1 (2.08) 
9  2 (4.17) 
PSA pre-op, mean (range)  5.79 (0.6 – 19.8) 
Adjuvant treatment (%)  
Radiotherapy  8 (16.67) 
Androgen deprivation 
therapy 
 5 (10.42) 
Chemotherapy       1 (2.08) 
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6. 2  Spectroscopy Result
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6. 3 Immunohistochemistry 
6. 3. 1  Evaluation of Prostate Immunomarker Stability after 
1
H HRMAS MRS 
Three cases of 28 paired tissue samples, which were studied for the evaluation of prostate 
immunomarker stability after 1H HRMAS MRS,  had to be excluded from further analyses 
due to insufficient gland epithelium in the cross-sections (stroma tissue only). 
The remaining 11 cases were used for the evaluation of quality and accessibility by the 
pathologist.  
P504S- positive staining, indicative of cancerous tissue, appeared in a distinct light brown, 
granular staining pattern in the tissue slides. CK903 on the other hand caused a clear, dark 
brown staining in the cytoplasm of benign epithelium basal cells, leaving cancerous tissue 
unstained.  P63, known as a basal cell marker, stained nuclei of benign prostate gland 
epithelium only. Due to its scattered nuclear staining pattern and the extensive background 
staining in most slides, the evaluation of this marker was complicated. Figure 28 illustrates 
the appearance of the three chosen prostate immunomarkers, P504S, CK903 and p63, in 
“unscanned” versus “scanned” tissue sections of the same prostate sample. 
The evaluation of quality was based on staining intensity, amount of background staining and 
similar criteria, using a 5- point scale. Table 6 summarizes the findings in the 28 paired tissue 
samples. 
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Figure 28: Immunohistochemical staining with the immunomarkers P504S (A1, A2), CK903 (B1, 
B2) and p63 (C1, C2) in prostate tissue cross-sections following 
1
H HRMAS MR spectroscopy 
(‘scanned’) and without prior scan (‘unscanned’). 
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Table 7: Quality of immunostainings in 14 scanned and matched unscanned tissue samples* 
Case 
number 
Unscanned Scanned 
Histopathological 
diagnosis 
P504S CK903 P63 P504S CK903 P63 
1 5 5 5 n 5 3 benign + cancerous 
2 5 5 4 5 n 2 benign + cancerous 
3 n 5 5 n 5 4 benign 
4 n 5 4 n 5 4 benign 
5 n 5 4 n 5 4 benign 
6 n 5 4 n 5 5 benign 
7 n 5 4 n 5 3 benign 
8 5 5 5 5 5 4 PIN 
9 5 n n 5 n n cancerous 
10 n 5 5 5 5 4 benign + cancerous 
11 n 5 4 n 5 3 benign 
12 n n n n n n no epithelium 
13 n n n n n n no epithelium 
14 n n n n n n no epithelium 
* n... no staining present in cross-section 
When comparing the quality evaluation scores between “scanned” and “unscanned” tissue 
samples for each of the three immunomarkers, no differences in the quality and evaluability 
could be found between the paired samples for both P504S and CK903. The immunostaining 
quality in the tissue sections stained after 1H HRMAS MRS was as good as in the instantly 
stained samples, graded a perfect score of 5 in all cases. 
For the third immunomarker p63 however, the quality and accessibility of the 
immunostainings showed significant differences between the “scanned” and “unscanned” 
tissue sections of each case (p=0.6728), found significantly decreased in most tissue samples 
after 1H HRMAS MRS. 
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Due to these results, P504S and CK903 were determined stable for IHC use after prior 
1H HRMAS MRS.  However, because of its decreased IHC quality and accessibility after 
1H HRMAS MRS, the marker p63 was excluded from all further immunohistochemical 
analyses.  
6. 3. 2  Qualitative Immunohistochemistry 
Using the immunomarker P504S to identify cancerous glands and CK903 to stain benign 
tissue, it was possible to distinguish between different histopathological conditions present in 
the sample cohort. All 51 cases were evaluated for the presence or absence of P504S- and 
CK903- staining, respectively. The presence of P504S- and absence of CK903-
immunostaining in the corresponding tissue slides was considered a positive qualitative 
diagnosis of PCa in the sample. Absence of P504S and presence of CK903, however, was 
classified as benign condition. Some of the tissue samples contained both benign and 
cancerous glands adjacent to each other. These cases were determined “mixed” immuno-
histopathology. Semi-malignant conditions, such as PIN were characterized by positive 
P504S- immunostaining as well as presence of staining for CK903. The benign condition  
BPH could be identified by absence of P504S and loss of CK903- immuno-positivity, mostly 
incomplete. 
Out of the 51 cases evaluated, six paired samples could not be diagnosed accurately due to the 
absence of glandular epithelium in the tissue. These cases were classified as “stroma only” 
and were excluded from further analysis. The remaining 45 cases showed presence of 
glandular epithelium and a positive color reaction in at least one of the two immunostainings. 
The following section illustrates the results of the qualitative IHC evaluation. 
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Pattern 1: “Mixed” immunohistopathology: both benign and cancerous glands 
In five cases, positive immunostaining for both P504S and CK903 was found in the glandular 
epithelia in mutually exclusive glands, suggesting the presence of both cancerous and benign 
glands in the samples (Figure 29). Light brown, granular staining in the P504S-slide and 
absence of staining in the exact same glands in the CK903-slide proofed the presence of 
cancer in the tissue. Other glands that were found to have a dark brown staining in the 
cytoplasm of the epithelium basal cells showed no signs of a color reaction on the 
corresponding P504S- slide, validating a benign condition. 
Figure 29: Co-existence of benign and malignant epithelium in two examples of tissue cross-
sections after IHC with P504S (left) and CK903 (right). 
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Pattern 2: Benign glands only
No signs of a color reaction on the P504S slides but dark brown cytoplasmatic staining in 
glandular basal cells in the corresponding CK903 slides indicated the presence of solely 
benign glands in the tissue sample (Figure 30). The majority of cases, 28 out of 44, showed 
this staining pattern indicating a predominantly benign sample cohort.
Figure 30: Three prostate tissue samples after IHC showing absence of P504S- staining (left 
panels) and clearly positive staining for CK903 (right panels), indicative of benign tissue. 
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Pattern 3: Cancerous glands only
Light brown granular staining in glands of the P504S slide with absence of any color reaction 
in the corresponding CK903 slide indicated the presence of solely cancerous glands in only 
one tissue sample in the entire cohort (Figure 31).
Figure 31: One single case in the cohort showed positive immunostaining for P504S (left) and 
negative reaction for CK903 (right), indicative of cancerous epithelium.  
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Pattern 4: Benign Prostate Hyperplasia (BPH)
Five cases in the cohort showed a staining pattern which was characterized by absence of 
staining in the P504S slides and an incomplete loss of CK903- positivity in the corresponding 
slides. This pattern was indicative of the benign condition BPH, in which the glands lose their 
normal cytokeratin expression (Figure 32). 
Figure 32: Two examples of the characteristic IHC- staining pattern indicative of BPH: absence of 
immunostaining for P504S (left) and partly positive CK903- staining due to loss of cytokeratin-
expression (right). 
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Pattern 5: Prostate Intraepithelial Neoplasia (PIN)
A very distinct staining pattern could be seen in five samples: Partly positive color reaction in 
the P504S slide with a partly positive staining for CK903 in the same glands in the 
corresponding slide. This pattern is typical for Prostate Intraepithelial Neoplasia, where the 
normal cytokeratin expression is reduced and P504S- expression is increased (Figure 33). 
Figure 34 summarizes the distribution of qualitative pathologies in the sample cohort. 
Figure 33: Characteristic pattern of IHC- staining for PIN: Positive staining in both P504S and 
CK903- stained tissue cross- sections in corresponding gland epithelium. 
���
�
Figure 34: Distribution of qualitative histopathological diagnoses in the sample cohort 
6. 4  Quantitative Immunohistochemistry
6. 4. 1  Quantitative IHC Slide Review 
Of the 51 evaluated cases, 15 exhibited positive staining for P504S, however, most of them 
only in a small percentage of tissue (only 5 cases had greater than 20% positively stained 
tissue). The majority of cases (42) showed CK903- positive tissue, corresponding with the 
previous findings in the qualitative  IHC analysis. Twelve cases showed both positive staining 
for P504S as well as for CK903. Out of these, seven cases exhibited staining for both markers 
in the exact same glands in the corresponding slides, indicating the presence of PIN in the 
tissue. In three cases, mutually exclusive glands showed P504S- and CK903- 
immunopositivity, indicating the presence of both cancerous and benign tissue. Two cases 
showed unspecific positive staining for P504S in predominantly benign tissue. Seven cases 
showed no gland epithelium and therefore, no positivity for immunostaining.  
The results of the quantitative IHC slide review can be viewed in Table 8. 
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Table 8: Centrally reviewed percentages of positively stained tissue  
Sample # P504S-positive (%) CK903-positive (%) Stroma (%) 
1 0 8 92 
2 35 15 50 
3 0 30 70 
4 0 20 80 
5 0 40 60 
6 0 60 40 
7 25 7.5 75 
8 0 15 85 
9 0 40 60 
10 0 15 85 
11 0 0 100 
12 0 15 85 
13 10 40 50 
14 0 20 80 
15 40 0 60 
16 0 0 100 
17 0 5 95 
18 5 15 80 
19 0 0 100 
20 0 12 88 
21 15 30 55 
22 0 8 92 
23 0 0 100 
24 8 32 60 
25 0 20 80 
26 0 28 72 
27 4 16 80 
28 0 20 80 
29 0 10 90 
30 5 0 95 
31 2 20 80 
32 0 15 85 
33 0 20 80 
34 0 10 90 
35 18 42 40 
36 20 20 80 
37 0 40 60 
38 7.5 17.5 75 
39 0 10 90 
40 0 15 85 
41 0 30 70 
42 0 50 50 
43 0 9 40 
44 0 20 80 
45 20 0 80
46 0 20 80 
47 0 12 88 
48 6 15 85 
49 0 0 100 
50 0 0 100 
51 0 0 100 
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6. 4. 2  Computer-Automated Quantitative IHC Evaluation using QIAP 
Observer-independent and objective quantitative IHC analysis was carried out using the 
MATLAB-based self-developed evaluation program QIAP (described in 4.3.4.2). Absolute 
and relative values of positively stained prostate gland epithelium, gland lumen area and 
stroma area in both P504S- and CK903- immunostainings were determined from digital 
images of IHC- processed cross-sections. 
As P504S- staining generally indicates the presence of cancerous epithelium, the percentage 
of cancer epithelium (CaE%) was estimated from the quantitative values of P504S- positively 
stained tissue. Similarly, the percentage of benign epithelium  (BenE%) was derived from the 
CK903- positively stained tissue. These estimations were made with the knowledge in mind 
that some P504S- positive conditions might not be cancer and some actually benign 
conditions might not express CK903.  
Ultimately, for each case, a cancer ratio was calculated from the percentages of cancer 
epithelium and benign epithelium:  In order to determine the value of cancerous tissue in each 
case, the CaE% was divided by the sum of CaE% and BenE%, representing the entire 
epithelium in each case. The individual percentages of cancerous and benign epithelia for 
each case are displayed in Table 9.  
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Table 9: Results of the quantitative IHC evaluation using QIAP 
Sample #
Cancer Epithelium % 
(CaE%) 
Benign Epithelium % 
(BenE%) 
1 0.086 6.012 
2 12.031 7.677 
3 0.106 13.932 
4 1.425 6.485 
5 0.541 11.221 
6 0.652 12.413 
7 0.728 1.539 
8 2.581 6.593 
9 3.221 12.670 
10 0.817 11.406 
11 1.241 0.513 
12 1.960 8.334 
13 2.096 6.821 
14 1.801 9.489 
15 36.926 0.130 
16 0.682 0.721 
17 1.762 3.798 
18 2.452 6.543 
19 1.378 3.500 
20 0.848 3.1967 
21 1.737 3.088 
22 8.263 5.943 
23 0.381 4.554 
24 0.015 0.046 
25 0.020 3.619 
26 0.329 1.182 
27 4.015 4.832 
28 0.040 5.186 
29 1.509 3.887 
30 0.934 3.163 
31 8.876 6.604 
32 4.402 6.895 
33 0.698 5.719 
34 0.188 13.685 
35 0.467 4.519 
36 0.371 14.235 
37 0.329 2.390 
38 0.634 6.610 
39 0.782 0.646 
40 2.532 0.414 
41 0.469 4.278 
42 0.147 7.660 
���
�
6. 5  Quantitative Histopathology 
Quantitative analysis of conventional H&E-stained tissue slides from each of the 51 cases was 
conducted to determine the percentages of cancerous and benign prostate glands in the cross-
sections. The percentages of all slides were averaged for each case (Table 10). To evaluate the 
utility of using a single adjacent slide as reference standard, the averaged percentages were 
compared to the quantitative measures of the cross-section directly adjacent to the slides used 
for IHC in a univariate analysis.  
The results of this comparison show that the averaged percentages of an entire case correlated 
significantly with the percentages obtained from a single adjacent slide for cancerous, benign 
tissue and stroma (p < 0.001 for all three analyses, Figure 35). 
Figure 35: Comparison of 
quantitative histopathology results 
between entire samples and one 
single slide adjacent to IHC slides: 
The averaged percentages of 
cancerous (A), benign tissue (B) and 
stroma (C) of complete cases 
correlate significantly with 
percentages obtained from a single 
slide (p < 0.001 for all).  
p < 0.001
A B 
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Table 10: Quantitative histopathology evaluation of complete samples and single adjacent slides
Sample # 
Cancer % Benign % Stroma % 
Complete Single Complete Single Complete Single 
1 �� �� �� ��� ��� ���
2 ��� ��� ��� ��� �� ��
3 �� �� ��� ��� ��� ���
4 �� �� ��� ��� ��� ���
5 �� �� ��� ��� ��� ���
6 �� �� ��� ��� ��� ���
7 ��� ��� �� �� ��� ���
8 �� �� ��� ��� ��� ���
9 �� �� ��� ��� ��� ���
10 �� �� ��� ��� ��� ���
11 �� �� �� �� ��� ���
12 �� �� ��� ��� ��� ���
13 �� �� ��� ��� ��� ���
14 �� �� ��� ��� ��� ���
15 ��� ��� �� �� ��� ���
16 �� �� �� �� ���� ����
17 �� �� �� �� ��� ���
18 �� �� ��� ��� ��� ���
19 �� �� �� �� ��� ����
20 �� �� ��� ��� ��� ���
21 �� �� �� �� ���� ����
22 �� �� �� �� ��� ���
23 �� �� �� �� ��� ���
24 �� �� ��� ��� ��� ���
25 �� �� ��� ��� ��� ���
26 �� �� ��� ��� ��� ���
27 �� �� ��� ��� ��� ���
28 �� �� ��� ��� ��� ���
29 �� �� ��� ��� ��� ���
30 �� �� �� �� ��� ���
31 �� �� ��� ��� ��� ���
32 �� �� �� ��� ��� ���
33 �� �� ��� ��� ��� ���
34 �� �� �� �� ��� ���
35 �� �� ��� ��� ��� ���
36 �� �� ��� ��� ��� ���
37 �� �� ��� ��� ��� ���
38 �� �� ��� ��� ��� ���
39 �� �� �� �� ��� ���
40 �� �� ��� ��� ��� ���
41 �� �� ��� ��� ��� ���
42 �� �� ��� ��� ��� ���
43 �� �� ��� ��� ��� ���
44 �� �� ��� ��� ��� ���
45 �� �� ��� ��� ��� ���
46 �� �� ��� �� ��� ���
47 �� �� ��� ��� ��� ���
48 �� �� ��� ��� ��� ���
49 �� �� �� �� ���� ����
50 �� �� �� �� ��� ���
51 ��� ��� �� �� ��� ���
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Furthermore, when comparing the results of the quantitative conventional histopathology 
analysis to the results obtained from the quantitative IHC slide review, the percentages of 
cancer determined by quantitative histopathology correlated significantly with the percentage 
of P504S- positive staining in the quantitative IHC slide review (p < 0.001). Similarly, the 
percentages of benign epithelium and stroma correlated between the quantitative 
histopathology and IHC readings (both p < 0.001).  
In order to validate the quantitative IHC results obtained with QIAP, the percentages of 
cancer epithelium and benign epithelium measured with QIAP were correlated to the 
percentages of P504S- positive and CK903- positive tissue determined by the pathologist, as 
well as to the results of the quantitative analysis of conventional histopathology.  
Cancer epithelium percentage (CaE%) as determined by QIAP showed a significant 
correlation to the percentage of P504S- positive tissue (p < 0.001) as well as to the percentage 
of cancer in the quantitative conventional histopathology analysis (p = 0.001). Similarly, the 
percentage of benign epithelium (BenE%) calculated by QIAP correlated significantly with 
the percentage of CK903- positive staining determined by quantitative IHC slide review  
(p < 0.001) and benign tissue percentage in quantitative conventional histopathology  
(p = 0.0183, Figure 36). 
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Figure 36: 
Comparison between the 
results of quantitative IHC 
obtained from QIAP and 
determined by pathologic 
slide review: Cancer 
epithelium percentage by 
QIAP correlates significantly 
with the percentage of 
P504S- positive tissue (A); 
benign epithelium percentage 
by QIAP correlates 
significantly with CK903-
positive tissue (B, p < 0.001). 
�
6. 6  Identification of Prostate Cancer Metabolomic Markers using QIAP 
QIAP presents a valid and feasible approach to automatically and objectively determine 
quantitative IHC results, as demonstrated in 5.4. Furthermore, the use of an automated 
quantitative IHC analysis yields the advantage of time- efficient, high- throughput objective 
analysis of immunohistochemistry.  
Therefore, in order to identify potential metabolomic markers for PCa, the relative spectral 
intensities obtained from 1H HRMAS MRS were correlated to the results of quantitative IHC 
analysis with QIAP of the exact same tissue sample using a linear regression analysis. 
A 
B 
p < 0.001 
p < 0.001 
���
�
Out of the 36 regions of interest (described in 4.2.3.), only two regions showed a significant 
correlation between the relative spectral intensities and CaE% as determined by QIAP. 
The relative spectral intensities at 3.22 ppm correlated significantly with the CaE% results 
obtained by QIAP with a p-value of 0.015, identifying this region as metabolomic marker for 
PCa (Figure 37). The metabolite corresponding to this region is phosphocholine (PCho). 
The second region for which a significant correlation of spectral intensities and CaE% was 
found, was the region 2.68 ppm (p = 0.0144). This region most closely corresponds to the 
metabolite citrate (Figure 38). 
Figure 37: Significant correlation between relative spectral intensities and cancer epithelium 
percentage (CaE%) determined by quantitative IHC analysis using QIAP at the region 3.22 ppm. 
Figure 38: Significant correlation between relative spectral intensities and cancer epithelium 
percentage (CaE%) determined by quantitative IHC analysis using QIAP at the region 2.68 ppm. 
���
�
The remaining 34 regions of interest did not show any correlation between spectral intensities 
and percentage of cancer epithelium. All graphs including the corresponding p- values for the 
correlation can be found in the Appendix section. 
In particular, the spectral intensities at the metabolomic region for lactate (1.32 – 1.34 ppm, 
p = 0.5334) as well as for creatine / phosphocreatine (3.03 ppm, p = 0.7427) did not correlate 
significantly with the percentage of cancer epithelium. Similarly, no significant correlations 
could be found in other common metabolites in prostate cancer, such as the regions 3.75 ppm, 
representing glutamine (p = 0.7545), 3.74 ppm, representing glutamate (p = 0.6097), or  
3.05- 3.09 ppm, the metabolomic region of spermine (p = 0.6025). 
6. 7  Patient Outcomes and Recurrence 
The outcomes of the patients in our cohort were determined 5 years following the initial 
diagnosis and prostatectomy surgery.  For four patients, no follow- up data was available. 
Two additional patients were followed for less than one year, considering them lost for 
follow- up. The remaining 45 patients were followed for an average time of 53.34 months 
(4.45 years), median follow- up 64.93 months (5.41 years), with a range between 14.53 and 
78.43 months (1.21 and 6.54 years). During the follow- up time, 14 patients received adjuvant 
treatment: radiotherapy in 8 cases (16.67%), androgen-deprivation therapy in 5 cases 
(10.42%) and chemotherapy in 1 case (2.08%). Table 11 summarizes the outcome results. 
Recurrence (PSA-elevation and / or new onset of clinical symptoms) was found in 11 patients 
(22.92%). However, the vast majority of patients (44, 97.78%) were alive at the time of last 
follow- up, with only one death found in the cohort. According to the classification of 
recurrence, 34 patients (75.56%) classified as recurrence category 1 (no recurrence), 7 
patients (15.56% ) belonged to the category 2 group (PSA-elevation without new clinical 
symptoms) and 4 patients (8.89%) were classified as category 4 (metastatic disease). No 
patients exhibited PSA-elevation and new onset of clinical symptoms (category 3, Figure 39).  
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Table 11: Outcome results 
Follow-up (%) 
        4 (7.84)    No follow-up  
< 12 months follow-up          2 (3.92) 
> 12 months follow-up        45 (88.24) 
Adjuvant treatment (%)  
Radiotherapy             8 (17.78) 
Androgen deprivation therapy           5 (11.11) 
Chemotherapy          1 (2.22) 
Recurrence (%)        11 (24.44)
Vital status at last follow up (%)  
Alive        44 (97.92) 
Dead          1 (2.22) 
Median follow-up  in months (years)        64.93 (5.41) 
Mean follow-up in months (years)           53.34 (4.45)  
Follow-up time range (months)          14.53 – 78.43  
Figure 39: Recurrence categories and percentages 
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A correlation between the recurrence categories and the relative spectral intensities obtained 
with 1H HRMAS MRS was performed in order to investigate for metabolomic markers of 
recurrence.  
Two metabolomic regions showed a significant correlation between the recurrence category 
and the relative spectral intensities present: the region 2.33 – 2.3 ppm (p = 0.0403) and the 
region 1.28 ppm (p = 0.0144). The metabolites most closely corresponding to these 
metabolomic regions are phosphocreatine (2.33 – 2.3 ppm) and lipids (1.28 ppm, Figure 40).
Figure 40: Recurrence category correlates significantly with the relative spectral intensities at the 
regions 2.33 – 2.3 ppm (A, p = 0.0403) and 1.28 ppm (p = 0.0144), indicating that these regions 
might represent metabolomic markers of PCa recurrence. 
p = 0.0144 
p = 0.0403 
B 
A 
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7 Discussion 
Summary of findings 
In this study, a novel approach to identify metabolomic markers of prostate cancer was 
estanlished, using prostate immunomarkers to quantify PCa metabolomic profiles measured 
from prostate tissue by 1H HRMAS MRS. 
In a first step, the potential of three prostate immunomarkers- P504S, CK903 and p63- to 
serve as tools for quantitative analysis of immunohistochemistry following 1H HRMAS MRS 
was explored. This study aimed to verify that both quality and accessibility of the prostate 
immunomarkers used for the quantitative analysis were not impacted by prior 1H HRMAS 
MR scanning, to ensure that these markers were suitable for post- spectroscopic IHC. For that, 
the quality and accessibility of immunostainings in prostate tissue samples that had undergone 
HRMAS 1HMR spectroscopy were analyzed and compared to “unscanned” tissue sections 
from the same samples. In this investigation, the immunomarkers P504S and CK903 showed 
equally excellent immunostaining quality in both “scanned” and “unscanned” tissue samples, 
indicating that these markers are stable for immunohistochemical use following 1H HRMAS 
MRS. The prostate immunomarker p63, however, showed significantly decreased quality of 
immunostaining after prior 1H HRMAS MRS, suggesting that this marker might not be useful 
for IHC analysis after 1H HRMAS MRS. 
Using the 1H HRMAS MRS- stable immunomarkers P504S and CK903, quantitative 
measures of the percentage of cancer present in the immunostained tissue sections were 
obtained, using the newly developed MATLAB-based quantitative image analysis program 
QIAP. The quantitative IHC results were validated, using quantitative measures of 
conventional histopathology and IHC judged by a pathologist.  
The percentage of cancerous (CaE%) and benign epithelia (BenE%) measured by QIAP 
correlated significantly with the results for cancer and benign tissue in the conventional 
histopathology slide review (p= 0.001 and p = 0.0183, respectively). Furthermore, CaE% and 
BenE% correlated significantly with the quantitative evaluation of cancer and benign tissue 
percentages as determined by the pathologist (p< 0.001 for both), indicating that the results of 
quantitative IHC measurements obtained with the program QIAP are valid and valuable for 
quantitative IHC analysis.  
Ultimately, in an attempt to validate the utility of quantitative IHC to identify metabolomic 
markers or PCa, relative spectral intensities obtained by 1H HRMAS MR spectroscopy were 
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correlated to the quantitative measures of cancer epithelium determined from immunostained 
slides of the same prostate sample, using QIAP. 
Out of 36 regions investigated, two regions showed a statistically significant correlation 
between quantitative IHC results and spectral intensities: 3.22 ppm (p = 0.0150) and 2.68 ppm 
(p = 0.0144). The metabolites corresponding to these regions, phosphocholine (PCho, 3.22 
ppm) and citrate (2.68 ppm) therefore have the potential to serve as metabolomic markers of 
cancerous epithelium in prostate tissue. 
Furthermore, patient outcomes five years after their initial surgery were obtained and PCa 
recurrence categories were identified in our cohort. Using the newly established quantitative 
IHC approach to identify metabolomic markers, metabolomic markers of recurrence could be 
identified in this study. Two metabolomic regions presented a significant correlation between 
recurrence grade and the relative spectral intensities: the region 2.33 – 2.3 ppm  
(p = 0.0403) and the region 1.28 ppm (p = 0.0144). The metabolites most closely 
corresponding to these metabolomic regions are phosphocreatine (2.33 – 2.3 ppm) and lipids 
(1.28 ppm). These results suggest that these metabolites could represent metabolomic markers 
of recurrence in PCa patients.  
Interpretation of the results 
The comparison of the quality and evaluability of immunostainings following 1H HRMAS 
MRS with those of “unscanned” tissue sections from the same prostate samples supports the 
hypothesis that the prostate tissue architecture remains intact during an 1H HRMAS MRS 
experiment. Multiple previous studies have established this knowledge [16, 37]. 
The equally excellent staining qualities in the stainings with the immunomarkers P504S and 
CK903 indicate that the immunologic potential is indeed preserved during a scan. These 
findings suggest that both markers, P504S and CK903, are stable for immunohistochemical 
use on prostate tissue samples previously studied by 1H HRMAS MRS.
In contrast, the quality and evaluability of the immunostainings with p63 were significantly 
decreased following 1H HRMAS MRS, indicating that this immunomarker might be 
susceptible to damage induced during the process of 1H HRMAS MRS scanning or post-
procession, or might lose its immunologic potential during the spectroscopy experiment. As 
the quality and the diagnostical value of p63-immunostainings appear to be altered through 
spectroscopy procedures, this immunomarker seems to be unuseful for IHC following 1H 
HRMAS MRS. The results of this study indicate that, although the tissue architecture remains 
stable after 1H HRMAS MRS, not all immunohistochemical procedures are feasible following 
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spectroscopic procedures. Prior to analyzing tissue scanned samples with IHC, the proposed 
immunomarker should therefore be tested for stability during the spectroscopic analysis. 
Ultimately, the quantitative analysis of combined immunostainings with P504S and CK903 
on adjacent tissue cross- sections presents a suitable diagnostic approach to quantitatively 
evaluate prostate tissue pathologic conditions and distinguish between benign and cancerous 
conditions in prostate tissue. While P504S indicates the presence of cancerous tissue, CK903 
identifies benign glands. Thus, the combination of these complementary antibodies highly 
increases the diagnostic value of the prostate cancer immunostaining. 
The significant correlations between the results of quantitative IHC analysis using the 
evaluation program QIAP and the results of a quantitative IHC review by an experienced 
pathologist strongly confirm that the program QIAP presents a valuable and valid method to 
determine quantitative measures of IHC. The fact that the results of QIAP also correlate 
significantly with the results of a quantitative conventional histopathology analysis further 
validates the utility of QIAP for quantitative pathological analysis. These findings show that 
QIAP presents a valid, objective and computer-automated approach for quantitative IHC 
analysis.  
Using quantitative IHC analysis and metabolomic profiles obtained with 1H HRMAS MRS, 
two metabolomic regions that significantly correlated with quantitative measures of cancerous 
epithelium in the samples were identified. The two metabolites corresponding to these 
regions, PCho and citrate, therefore could be identified as metabolomic markers of prostate 
cancer conditions in our cohort. PCho is a ubiquitous metabolite, mostly present in cell 
membranes, and involved in the pathway of choline synthesis. PCa causes high cell 
proliferation and an increase in cell membrane synthesis, which results in elevated choline 
levels and an elevation of choline synthesis meta-products, like PCho, glycerophosphocholine 
and free choline [93]. Although PCho is an unspecific metabolite, its increased concentration 
in cancerous conditions might contribute to its potential as a metabolomic marker of PCa. 
Citrate is a metabolite highly characteristic of healthy prostate tissue and prostate fluids. 
Under normal conditions, high levels of citrate are generally found. Malignant conditions, 
such as PCa, cause a pathological oxidation of citrate in the KREBS cycle, resulting in a 
significant decrease of citrate levels.  A decrease in the citrate signals as well as in the 
citrate/creatine- and (choline + creatine)/citrate- ratios in prostate spectroscopy are commonly 
acknowledged indicators of the presence of cancer. The identification of citrate as a 
metabolomic marker of PCa seems therefore plausible. A quantification of citrate seems to be 
���
�
a feasible approach and could potentially increase the diagnostic value of prostate 
spectroscopy.  
Comparison of the results with findings of other studies 
Multiple previous studies have focused on creating metabolomic profiles for PCa, using NMR 
spectroscopy [61, 94] and mass spectrometry methods [67, 95]. However, due to technical 
challenges in this field, previous results are highly diverse and different metabolites have been 
proposed as potential biomarkers for PCa [36, 96-98]. 
The association between changes in choline-containing metabolites and malignant 
transformation is well established [99]. Increased expression of genes involved in choline 
metabolism and transport, such as choline kinase, kinase have been found in different cancers, 
including breast cancer or high- grade gliomas [100, 101], but also PCa. Choline and choline 
compounds have been shown to be increased in prostatectomy as well as prostate biopsy 
specimen in cancer patients versus matched benign tissue samples [60, 68]. Also, previous ex 
vivo studies have found increased Pcho levels to be associated with increased PSA and higher 
GLEASON score, indicating the importance of this biomarker for the detection and 
classification of prostate cancer [50, 60]. PCho is a metabolite involved in the pathway of 
choline synthesis. Because of its association to alterations in cell membrane synthesis, choline 
levels are increased in PCa, resulting in an elevation of choline synthesis meta-products, like 
PCho, glycerophosphocholine and free choline [93]. Not only increased cell proliferation, but 
also changes in tumor microenvironment, like hypoxia or shifts of pH, account for alterations 
in choline metabolite levels� ��� ����� ��� ������ ���������� �������������� ������� ��������
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Other metabolites have been suggested to present biomarkers of PCa in past studies. Lactate 
and alanine are known to be increased in PCa, due to enhanced glycolytic activity and the 
Warburg effect [61, 68]. However, these biomarkers are unspecific metabolites which are
altered in multiple cancer types, thereby reducing their potential to be PCa specific 
biomarkers. With p- values of 0.5334 (region 1.32 – 1.34 ppm) and 0.7828 (region 1.46 ppm) 
respectively, the spectroscopic regions corresponding to lactate and alanine did not show 
significant correlations to CaE% in the present study. With the established dataset, it was not 
possible to identify these metabolites as biomarkers for PCa.  
In contrast to the unspecific metabolites mentioned before, decreased levels of citrate, zinc 
and spermine are associated more specifically with prostate cancer [103]. 
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Decreased levels of citrate have previously been observed in prostate cancer tissue by ex vivo
MRS [68] and measurements of citrate signals and metabolite ratios including citrate have 
successfully been incorporated into routine clinical diagnostics [104, 105]. In accordance with 
the results of this study, citrate has been suggested to present a PCa biomarker in a previous 
study using ex vivo1H HRMAS MRS [50]. In a recent study, citrate was additionally found to 
be associated with cancer aggressiveness. The authors reported a negative correlation between 
citrate levels and the GLEASON score as well as significant differences between low grade 
and high grade PCa, indicating that citrate concentrations measured by MRS have the 
potential to distinguish between highly aggressive and indolent PCa cases [106].  
Besides changes in citrate levels, a decrease of polyamine signals has been found to be 
associated with PCa [50]. Significantly lower concentrations of spermine have been reported 
in high grade compared to low grade PCa, suggesting spermine to be a discriminative 
biomarker for PCa aggressiveness [106]. Polyamines, especially spermine, have a strong 
potential for incorporation into clinical practice. In the present study, an association between 
cancer epithelium percentage and spectral intensities for the region of spermine (3.05 – 3.09 
ppm, p = 0.6025) could not be confirmed. 
Other metabolomic biomarkers described in the literature include myo-inositol, taurine, 
valine-leucine, glutamine and hydroxybutyrate [63]. None of these metabolites could be 
identified using the presented  novel approach, most likely due to the predominantly benign 
nature of the sample set. A recent study using LC/ GC-MS to identify PCa metabolomic 
markers, found six metabolites that were associated with PCa and its progression: sarcosine, 
uracil, kynurenine, glycerol-3-phosphate, leucine and proline [67]. Among them, sarcosine 
demonstrated the most pronounced differences, suggesting its strong potential as a biomarker 
for PCa and leading to further extensive investigations of this metabolite [107-109]. In the 
present study, none of these recently suggested metabolomic biomarkers could be confirmed 
to be associated with PCa when using quantitative IHC as investigative tool. Multiple reasons 
and limitations of our aporoach might account for that, which will be illustrated in the 
following section. 
Limitations of the study 
Limitations of this study are due in part to the heterogenous sample cohort with 
predominantly benign tissues. Out of each prostatectomy sample, only a small amount of 
tissue was studied, therefore not guaranteeing definitive evaluation of the cancerous portion. 
Also, the sample cohort contained preliminary stages of malignant conditions, such as BPH or 
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PIN. Because of this, a clear evaluation of metabolite markers for cancer was difficult to 
realize. In order to establish validate prostate cancer metabolomics profiles, more cases with 
predominantly cancerous conditions would need to be studied. 
Due to difficulties in spectroscopy or quantitative image evaluation, only 42 out of the 51 
cases could be subjected to quantitative analysis, substantially reducing the sample cohort. 
The MATLAB-based evaluation program used for the quantitative image evaluation is a self-
developed pioneer image evaluation program. Therefore, the results of this method have to be 
considered with caution. Further improvements of the program are necessary in the future. For 
instance, image brightness should be adjusted and a fixed, and a user- independent threshold 
for each immunomarker employed. To ensure program improvement, bigger sample sizes 
need to be evaluated using this device. First and foremost, the current results should be 
validated using a larger sample cohort of predominantly cancerous tissue.  Also, a cumulative 
analysis of the tissue samples, including all cross- sections of each individual sample, would 
be useful. Ultimately, a 3- dimensional sample analysis seems to be desirable, as it allows full 
analysis of all tissue components. 
This study was performed ex vivo, using a 600MHz MR spectrometer. Translation of the 
results into an in vivo clinical application is challenging. Routine clinical scanners usually 
have field strengths of 3T or 1.5T, and thus provide a lower spectral resolution and more 
prominent baseline noise than high field spectrometers. 7T in vivo scanners provide more 
accurate results and could help overcoming these challenges, but are not available for routine 
clinical diagnostics in most centers. To date, the strongest MR scanner available for in vivo
use in human subjects has a field strength of 10.5T and is located at the University of 
Minnesota in Duluth, MN, USA [110].The NeuroSpin facility in France is currently 
constructing an 11.7T whole- body human scanner which is expected to be available for 
research purposes in 2014 [111]. Due to artifacts and side effects experienced by the subjects, 
the use of even stronger magnets will not be possible in the near future, thus impairing a 
direct translation of the 14.1T spectroscopy results established in this study into an in vivo 
application. Besides, spectroscopy is more time- consuming, more difficult to evaluate and 
more expensive than other methods. 
Magic Angle Spinning, the central method used in this study, is a highly optimized technique 
which enables an extremely high resolution in an ex vivo setting. However, MAS can never be 
performed in humans, as a human body would not be able to tolerate spinning in a scanner. 
Therefore, the extremely high resolution achieved in with a MAS- rotor will never be 
reproducible in an in vivo application. 
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Ultimately, in order to establish clinical applicability of our results, metabolomic profiles 
established by ex vivo 1H HRMAS MRS would have to be translated into an in vivo setting, 
while at the same time increasing the quality of low field spectroscopy and reducing scan time 
and costs. 
As part of our investigations, patient outcomes were determined 5 years after prostatectomy. 
Early identified and correctly treated prostate cancer has a very favorable prognosis, with a 
5-year-survival time of close to 100% [112]. Therefore, at the time of last follow-up, the vast 
majority of patients in our cohort were still alive, limiting the conclusions that could be drawn 
from correlations of spectroscopy and outcome measures.  
Strengths 
Despite those limitations, the presented approach using quantitative evaluation of IHC clearly 
yields great potential for clinical applicability. In contrast to conventional histopathology 
using H&E staining, IHC is an objective, observer- independent method and has the potential 
to be computer- automated. Through visualization of immunohistochemical reactions with 
DAB, subsequent quantitative, in contrast to qualitative, evaluation is possible, as shown by 
this study. Using this approach, high- throughput evaluation of large cohorts of 
immunostained prostate tissue samples could be possible, realizing the establishment of valid 
and accurate metabolomic profiles that could then be used in a clinical setting. These 
metabolomic profiles could aid in accurate differentiation between benign and malignant 
conditions, as well as between low and high grade cancer. Ultimately, objective and 
extremely fast evaluation of prostatectomy- specimen or biopsies could be feasible in the 
future, without the need for an independent pathologist. A translation of metabolomics 
profiles established with our method into an in vivo setting is possible, and could present a 
non- invasive diagnostic approach for accurate classification of disease, even in a pre-
operative setting. Longitudinal, non-invasive monitoring of PCa patients would be possible, 
and recurrent disease could be better distinguished from other non- malignant conditions. 
In this study, the patient outcome and recurrence categories were determined and correlated in 
order to identify metabolomic markers of recurrence. The vast majority of patients (88.24%) 
were followed tightly for the entire time- period of 5 years, adding great additional value to 
the results of spectrocopy and IHC. 
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Outlook  
Given the exploratory nature of the study, the presented findings must be considered in a 
hypothesis generating context. Further studies are needed to verify the identified prostate 
cancer metabolomic markers phosphocholine and citrate, as well as to establish the clinical 
applicability of this novel method. A high- throughput analysis of a large cohort of PCa 
samples (e.g. biopsies or prostatectomy samples) with this novel approach could aid in the 
development of accurate metabolomics profiles to differentiate several conditions, such as 
highly aggressive cancer from indolent cases or precursor lesions. Even an objective, accurate 
staging could be accomplished, by differentiating biopsy samples or prostatectomy samples 
according to metabolomics profiles of different GLEASON grades. A future aim should be a 
translation of metabolomic profiles of PCa into an in vivo setting. Ultimately, a non-invasive 
approach to longitudinally monitor disease status and help to identify recurrence in PCa 
patients would be of great clinical importance. 
The patients enrolled in this study were followed for 5 years after initial surgery to determine 
outcome and recurrence. A prospective patient follow- up for an even longer time (10 years or 
more) could add additional knowledge to and determine more accurate measures of outcome 
and survival.  In order to improve PCa metabolomics profiles and confirm previous results of 
metabolomic predictors of aggressive behavior, these outcomes could be correlated with  
1H HRMAS MRS results as well as quantitative pathology using IHC in future studies. 
Conclusion 
In this study, a novel method was introduced that allows for an observer- independent, 
quantitative analysis of IHC to help establish metabolomic profiles and identify metabolomic 
markers of PCa from spectral intensities obtained with 1H HRMAS MRS. The combination of 
1H HRMAS MRS and IHC has the potential to serve as faster, more accurate, observer-
independent diagnostic tool. 1H HRMAS MRS could become a useful tool in the diagnostics 
of PCa. Biopsies of patients that are suspected of having PCa could be subjected to  
1H HRMAS MRS and the results compared to pre-established cancer profiles. Thus, a 
differentiation between highly malignant and aggressive conditions that requires radical 
therapy or rather low malignant, non-aggressive tumors that can be treated with “watchful 
waiting”, would be possible. A prospective in vivo application of PCa metabolite profiles and 
metabolomic markers could serve as highly sensitive, non- invasive diagnostic tool. 
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Observer- independent, computer- automated tissue evaluation could help to avoid 
overtreatment and reduce complications and risks from invasive methods for PCa patients in 
the future. 
�
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8 Summary / Abstract 
Background 
Prostate cancer (PCa) is the most frequently diagnosed malignant disease among adult males 
in the USA and the second leading cause of cancer deaths in men. Due to the lack of 
diagnostic tools that are able to differentiate highly malignant and aggressive cases from 
indolent tumors, overtreatment has become very common in the era of prostate specific 
antigen (PSA) screening. New diagnostical methods to determine biological status, 
malignancy, aggressiveness and extent of PCA are urgently needed. 1H High Resolution 
Magic Angle Spinning Nuclear Magnetic Resonance Spectroscopy (1H HRMAS MRS) can be 
used to establish PCa metabolomic profiles while preserving tissue architecture for 
subsequent histopathological analysis. Immunohistochemistry (IHC), as opposed to 
conventional histopathology methods, has the potential to provide objective, more accurate 
and quantitative knowledge of tissue pathology. This diagnostic- accuracy study sought to 
evaluate a novel approach to quantitatively identify metabolomic markers of PCa by 
exploring the potential of PCa immunomarkers to quantify metabolomic profiles established 
by 1H HRMAS MRS. 
Material and Methods 
1H HRMAS MRS was performed on tissue samples of 51 prostate cancer patients using a  
14.1 T BRUKER NMR spectrometer with a rotor synchronized CPMG pulse sequence. 
Spectral intensities of 36 regions of interest were measured as integrals of curve fittings with 
Lorentzian-Gaussian line shapes. Immunohistochemistry (IHC) was carried out following the 
spectroscopy scan, using three prostate immunomarkers to identify cancerous and benign 
glands: P504S (Alpha-methylacyl-CoA-racemace), CK903 (high-molecular weight 
cytokeratin) and p63.The immunostaining quality following 1H HRMAS MRS was evaluated 
and compared to unscanned sections of the same sample, to verify the stability and 
accessibility of the proposed immunomarkers. IHC images were automatically and 
quantitatively evaluated, using a quantitative image analysis program (QIAP), to determine 
the percentage of cancerous and benign epithelia in the cross- sections. The results of the 
program were validated by a correlation to the results of a quantitative IHC review and 
quantitative conventional histopathology analysis performed by an experienced pathologist.  
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Ultimately, spectral intensities and the cancer epithelium percentage, obtained from 
quantitative immunohistochemistry, were correlated in order to validate PCa metabolomics 
markers identified by 1H HRMAS MRS. 
Patient outcomes and incidence of recurrence were determined by retrospective review of 
medical records five years after initial surgery. States of recurrence were correlated to spectral 
intensities to explore potential metabolomics markers of recurrence in the cohort.  
Results 
Immunostainings with P504S and CK903 showed excellent staining quality and accessibility 
following 1H HRMAS MRS, making these markers suitable for our novel quantitative 
approach to determine metabolomics profiles of PCa. In contrast, the quality of p63 IHC was 
impaired after previously performed spectroscopy.  
IHC using the immunomarkers P504S and CK903 on adjacent slides presents a feasible 
quantitative diagnostic method to distinguish between benign and cancerous conditions in 
prostate tissue. The cancer epithelium percentage as determined by QIAP showed a 
significant correlation to the results of quantitative IHC analysis performed by a pathologist  
(p < 0.001), as well as to a quantitative conventional histopathology review (p = 0.001). The 
same was true for the benign epithelium percentage (p < 0.001 and p = 0.0183), validating our 
novel approach.  
Two metabolomic regions showed a significant correlation between relative spectral 
intensities and the cancer epithelium percentage as determined by QIAP: 3.22 ppm  
(p = 0.015) and 2.68 ppm (p = 0.0144). The metabolites corresponding to these regions, 
phosphocholine and citrate, could be identified as metabolomic markers of PCa in our cohort. 
45 patients were followed for more than 12 months. Of these, 97.8%were still alive five years 
after initial surgery. 11 patients (24.4%) experienced a recurrence during the follow- up time. 
The categories of recurrence showed a correlation to the spectral intensities of two regions, 
2.33 – 2.3 ppm (p = 0.0403) and 1.28 ppm (p = 0.0144), corresponding to the metabolites 
phosphocreatine and lipids. 
Conclusion 
This study introduces a method that allows an observer-independent, quantitative analysis of 
IHC to help establish metabolomic profiles and identify metabolomic markers of PCa from 
spectral intensities obtained with 1H HRMAS NMR Spectroscopy. The immunomarkers 
P504S and CK903 have been found suitable IHC analysis following 1H HRMAS MRS. A 
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prospective in vivo application of PCa metabolite profiles and metabolomic markers 
determined by our analysis could serve as highly sensitive, non- invasive diagnostic tool. This 
observer- independent, computer- automated, quantitative analysis could help to distinguish 
highly aggressive tumors from low-malignant conditions, avoid overtreatment and reduce 
risks and complications for cancer patients in the future. However, further studies are needed 
to verify the identified PCa metabolomic markers and to establish clinical applicability. 
�
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9  Zusammenfassung 
Einführung 
Prostatakrebs ist eine häufigsten Krebserkrankungen in den USA und die zweithäufigste 
malignom- assoziierte Todesursache  männlicher Patienten weltweit. Seit der Einführung des 
Prostata- spezifischen Antigen (PSA)- Screeningtests wird diese Krebsart in früheren Stadien 
diagnostiziert und therapiert, wodurch die Mortalitätsrate in den letzten Jahren deutlich 
reduziert werden konnte. Da moderne diagnostische Methoden bislang jedoch nicht 
ausreichend in der Lage sind, suffizient zwischen hochmalignen und weniger aggressiven 
Varianten dieses bösartigen Krebsleidens zu unterscheiden, werden häufig auch Patienten 
aggressiv therapiert, deren niedriggradiges Prostatakarzinom keine klinische Relevanz gehabt 
hätte. Es besteht daher ein großes wissenschaftliches Interesse an der Entwicklung neuer 
diagnostischer Methoden zur akkuraten Bestimmung von biologischem Status, Malignität, 
Aggressivität und Ausmaß einer Prostatakrebserkrankung. 
"1H High Resolution Magic Angle Spinning Nuclear Magnetic Resonance Spectroscopy" (1H 
HRMAS MRS) ist eine vielversprechende diagnostische Methode, welche es ermöglicht, 
metabolomische Profile von Prostatakrebs zu erstellen, ohne die Gewebsstruktur der 
analysierten Proben zu zerstören. Durch anschließende histopathologische Begutachtung 
lassen sich die erstellten Metabolitprofile validieren und evaluieren.  
Im Gegensatz zu konventionellen histopathologischen Methoden können  durch 
immunhistochemische Verfahren dabei objektivere, akkuratere und quantifizierbare 
histopathologische Erkenntnisse gewonnen werden. 
Die vorliegende Studie präsentiert einen neuentwickelten diagnostischen Ansatz zur 
quantitativen Bestimmung von metabolomischen Markern von Prostatakrebs, basierend auf 
der Durchführung von 1H HRMAS NMR Spektroskopie und quantitativer 
Immunhistochemie.  
Material und Methoden 
Einundfünfzig Gewebsproben von Prostatakrebspatienten wurden mittels 1H HRMAS MRS 
an einem 14.1 T BRUKER NMR Spektrometer unter Einsatz einer CPMG-Pulssequenz 
untersucht. Spektrale Intensitäten in 36 Metabolitregionen wurden gemessen. Anschließend 
wurden die analysierten Gewebeproben mit drei Immunfärbemarkern für sowohl malignes 
(P504S, Alpha-methylacyl-CoA-racemase) als auch benignes (CK903, High-molecular 
weight cytokeratin, und p63) Prostatagewebe angefärbt und quantitativ mit Hilfe eines 
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Bildanalyseprogramms (QIAP) ausgewertet. Die Anwendbarkeit und Auswertbarkeit der 
genannten Immunomarker  nach Spektroskopie wurde evaluiert und mit der Färbungsqualität 
von nicht- gescannten Schnitten verglichen.  
Die Resultate der automatischen Auswertung durch QIAP konnten durch einen erfahrenen 
Pathologen in einer quantitativen Analyse der Immunfärbungen sowie konventioneller  
histologischer Färbungen derselben Gewebsproben validiert werden. Die spektralen 
Intensitäten aus den Messungen mit 1H HRMAS MRS wurden mit den korrespondierenden 
Ergebnissen der quantitativen Auswertung der Immunfärbungen korreliert, um 
metabolomische Marker von Prostatakrebs zu identifizieren.  
Der klinische Verlauf und die Rezidivrate der Patienten wurden 5 Jahre nach der initialen  
Prostatektomie retrospektiv bestimmt.  Rezidivkategorien wurden erstellt und mit den 
bestimmten spektralen Intensitäten korreliert, um metabolomische Marker für das Auftreten 
von Prostatakrebsrezidiven zu identifizieren. 
Ergebnisse
Die Immunfärbungen mit P504S und CK903 zeigten exzellente Qualität und Auswertbarkeit 
nach vorheriger 1H HRMAS MRS. Beide Marker eigneten sich zur Durchführung von 
quantitativer Immunhistochemie an spektroskopierten Gewebeproben. Im Gegensatz dazu war 
die Qualität der Immunfärbungen mit p63 nach Spektroskopie vermindert. Quantitative 
Immunfärbungen unter Einsatz der Immunmarker P504S und CK903 stellten eine praktikable 
diagnostische Methode dar, um zwischen malignen und benignem Prostatagewebe zu 
unterscheiden.  
Der Anteil von bösartig verändertem Prostatagewebe, bestimmt durch QIAP, korrelierte 
signifikant  mit den Ergebnissen der quantitativen Analyse der Immunfärbungen durch den 
Pathologen (p < 0.001), sowie mit der quantitativen Auswertung der konventionellen 
histopathologischen Färbung (p = 0.001). Ebenso ließ sich die Bestimmung des Anteils von 
benignem Gewebe mit QIAP zu den Ergebnissen der pathologischen Analyse korrelieren 
(p < 0.001 und p = 0.0183).  
Für zwei metabolomische Regionen konnte ein signifikante Korrelation zwischen relativen 
spektralen Intensitäten, bestimmt mit 1H HRMAS NMR Spektroskopie, und dem Anteil von 
malignem Epithelium in derselben Gewebeprobe, ermittelt durch QIAP,  festgestellt werden: 
3.22 ppm (p = 0.015) und 2.68 ppm (p = 0.0144). Die zu diesen Regionen korrespondierenden 
Metaboliten, Phosphocholin und Zitrat, konnten als potentielle metabolomische Marker für 
Prostatakrebs identifiziert werden.  
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Die retrospektiven Analyse der klinischen Daten der Patienten fünf Jahre nach Prostatektomie 
ergab eine Überlebensrate von 97.8%. Elf dieser Patienten (24.4%) erlitten ein Rezidiv ihrer 
Erkrankung. Die bestimmten Rezidivkategorien korrelierten signifikant mit zwei 
metabolomischen Regionen (2.33 – 2.3 ppm, p = 0.0403 und 1.28 ppm, p = 0.0144), welche 
zu den Metaboliten Phosphokreatin und Lipiden korrespondierten. 
Schlussfolgerung 
Die vorliegende Studie präsentiert einen diagnostischen Ansatz zur objektiven und 
quantitativen Bestimmung metabolomischer Marker von Prostatakrebs unter Verwendung von 
1H HRMAS MRS und Immunhistochemie.  
P504S und CK903 eignen sich als Immunmarker für quantitative Immunfärbungen nach 
vorheriger Durchführung von 1H HRMAS MRS.  
Die Metaboliten Phosphocholin und Zitrat konnten in der vorliegenden Patientenkohorte als 
potentielle metabolomische Marker für Prostatakrebs identifiziert werden. 
Eine mögliche in vivo Anwendung der gefundenen metabolomischen Marker könnte als 
hochsensitives, objektives und nicht- invasives diagnostisches Werkzeug der 
Prostatakrebsdiagnostik dienen. Der vorliegende untersucherunabhängige, automatisierte und 
quantitative diagnostischer Ansatz hat das Potential, zwischen hochmalignen und weniger 
aggressiven Krebsfällen zu unterscheiden und somit unnötige Risiken und Komplikationen 
für Prostatakrebspatienten zu reduzieren. 
Weitere Untersuchungen sind notwendig, um die identifizierten metabolomischen Marker zu 
verifizieren und eine klinische Anwendung zu etablieren.  
�
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Appendix 
A.1  Staining Protocols 
Table A1: IHC staining procedure summary
P504S CK903 P63 
Preparation Deparaffinization and dehydration 
Antigen retrieval 
TRIS/EDTA buffer 
(pH 9.0, 10mM/1mM) 
30 min 
Citrate buffer 
(pH 6.0, 0.1mM) 
30 min 
Quenching of 
endogenous peroxides 
3% H2O2 in methanol 
10min 
Protein block 
Protein block solution 
3-4 drops (150-200µl), 10min 
First incubation:  
primary antibody 
Rabbit monoclonal 
anti-human AMACR, 
200 µl, 75 min 
Mouse monoclonal 
anti-human CK903, 
200 µl, 75 min 
Mouse monoclonal 
anti-human p63, 
200 µl, 75 min 
Buffer wash PBS, 5 min 
Second incubation: 
secondary antibody
Biotinylated 
anti-rabbit IgG (1:50), 
150µl, 30 min 
Biotinylated 
anti-mouse IgG (1:50), 
150µl, 30 min 
Buffer wash PBS, 5 min 
Third incubation 
Avidin / Biotin / Peroxidase complex (ABC), RTU agent 
5-6 drops, 30 min 
Visualization 
Diaminobenzidine-3,3’ 
250µl, 10 min 
Post-processing Counterstain, Dehydration, Cover slip 
����
�
Table A2: Hematoxylin & Eosin – staining protocol 
Immunostaining step Chemicals / Agents applied Time
Deparaffinazation and rehydration Xylene I 5 min 
Xylene II 5 min�
Xylene III 5 min�
100% EtOHI 5 min�
100% EtOHII 5 min�
95% EtOH 5 min�
70% EtOH 5 min�
deionized H2O  I 5 min 
deionized H2O  II 5 min 
Hematoxylin & Eosin staining Hematoxylin 4 min 
deionized H2O 3 min�
Sodium Borate 4% in H2O 1 dip�
95% EtOH 2 min�
Eosin 3.5 min�
Dehydration and fixation 95% EtOH 3 dips�
95% EtOH 3 dips�
100% EtOHI 1 min�
100% EtOHI 1 min�
Xylene I 5 min 
Xylene II 5 min 
Permanent mounting media ����������
�
�
�
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�
A.2 Spectral Intensities Measured by 
1
H HRMAS MRS in 51 Samples 
�
Table A3: Spectral intensities in samples 1-10 
ROI / Sample 1 2 3 4 5 6 7 8 9 10 
4.14-4.11 0.04221 0.01318 0.02364 0.01668 0.01899 0.02933 0.02575 0.02318 0.02979 0.02798 
4.05 0.02668 0.00873 0.02842 0.01221 0.01602 0.02174 0.01436 0.02063 0.02134 0.02690 
3.99-3.96 0.00000 0.00523 0.00000 0.00000 0.00072 0.01272 0.00914 0.00000 0.00248 0.00000 
3.94-3.93 0.01262 0.06418 0.00595 0.00000 0.01033 0.00586 0.01346 0.02494 0.00889 0.01444 
3.78 0.00012 0.00000 0.00000 0.00000 0.00020 0.00130 0.00093 0.00374 0.00289 0.00000 
3.75 0.00082 0.00000 0.03191 0.00000 0.00000 0.00103 0.00170 0.00023 0.00079 0.00420 
3.74-3.71 0.00018 0.00000 0.00000 0.00000 0.00250 0.20307 0.00444 0.00160 0.00085 0.00156 
3.63 0.00549 0.00217 0.00521 0.01534 0.01035 0.00000 0.00000 0.00369 0.00262 0.00436 
3.62 0.01556 0.00674 0.01818 0.02754 0.01437 0.00427 0.00312 0.01353 0.00975 0.01501 
3.6 0.01018 0.00356 0.01442 0.02066 0.00836 0.02012 0.01004 0.00690 0.00421 0.00678 
3.34 0.00115 0.01318 0.00576 0.00695 0.00770 0.01243 0.00336 0.00561 0.00475 0.00708 
3.29 0.00264 0.00000 0.00106 0.00344 0.00153 0.00035 0.00000 0.00120 0.00124 0.00316 
3.27 0.00176 0.00216 0.00806 0.01576 0.00807 0.00459 0.00012 0.00920 0.00773 0.01324 
3.26 0.04476 0.00904 0.01348 0.01920 0.01405 0.01301 0.00000 0.02680 0.00745 0.02342 
3.24 0.00000 0.00193 0.00734 0.00000 0.00000 0.02925 0.00760 0.00000 0.00158 0.00000 
3.22 0.00947 0.01749 0.01281 0.01486 0.01970 0.02749 0.00294 0.01533 0.01077 0.01174 
3.2 0.03190 0.02538 0.02014 0.02161 0.01597 0.07432 0.02424 0.01634 0.01309 0.02254 
3.15-3.1 0.01193 0.00000 0.00291 0.00630 0.00329 0.01149 0.00000 0.00724 0.06425 0.00723 
3.09-3.05 000000 0.00000 0.00010 0.00000 0.00000 0.03821 0.00000 0.01463 0.02582 0.00838 
3.03 0.01341 0.01487 0.01284 0.00958 0.00992 0.00811 0.00197 0.01965 0.00996 0.01897 
2.71 0.01142 0.01469 0.00677 0.02526 0.00878 0.00372 0.00000 0.00824 0.01521 0.01603 
2.68 0.00559 0.01028 0.00667 0.01534 0.01268 0.02947 0.00000 0.00958 0.01071 0.01272 
2.55 0.00418 0.00964 0.00530 0.01813 0.00117 0.01012 0.00465 0.01747 0.01565 0.01079 
2.52 0.00509 0.02215 0.00678 0.01519 0.01157 0.00336 0.00386 0.01267 0.00883 0.02335 
2.45-2.43 0.00000 0.00000 0.00000 0.00000 0.00000 0.01784 0.00000 0.00273 0.00000 0.00000 
2.42-2.4 0.00096 0.00000 0.00070 0.00090 0.00000 0.00773 0.00217 0.00927 0.00144 0.00000 
2.36 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00159 
2.35 0.00594 0,00000 0.00181 0.00128 0.00113 0.00000 0.00000 0.01173 0.00000 0.00251 
2.34 0.00000 0,00947 0.00327 0.00481 0.00341 0.00000 0.00117 0.00000 0.00445 0.00334 
2.33-2.3 0.00630 0,00000 0.00193 0.00418 0.01287 0.00861 0.02204 0.00906 0.00000 0.00331 
1.48-1.46 0.00222 0,00490 0.00617 0.00487 0.00402 0.00000 0.00388 0.00201 0.00653 0.00292 
1.34-1.32 0.15193 0,06688 0.10292 0.12103 0.10623 0.00117 0.03057 0.09805 0.07438 0.09194 
1.28 0.02794 0,02327 0.01163 0.00000 0.02217 0.00000 0.07079 0.02371 0.00000 0.02380 
1.2 0.00000 0.0000 0.00085 0.00014 0.00000 0.00000 0.00002 0.00000 0.00661 0.00000 
0.96-0.93 0.00838 0.00657 0.01206 0.01440 0.01556 0.00000 0.00803 0.00947 0.00783 0.01552 
0.9 0.01847 0.01545 0.00001 0.00040 0.00443 0.00000 0.00409 0.00911 0.00792 0.00329 
�
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Table A4: Spectral intensities in samples 11 - 20 
ROI / Sample 11 12 13 14 15 16 17 18 19 20 
4.14-4.11 0.01227 0.02898 0.03277 0.04463 0.03383 0.01727 0.02322 0.01972 0.01443 0.03933 
4.05 0.02054 0.02961 0.01816 0.07243 0.01526 0.01144 0.02421 0.01508 0.01120 0.02084 
3.99-3.96 0.00000 0.03721 0.00693 0.17284 0.00976 0.00298 0.00805 0.00493 0.00000 0.00000 
3.94-3.93 0.00669 0.04435 0.01336 0.03225 0.01231 0.02520 0.00743 0.00922 0.01251 0.00661 
3.78 0.00254 0.00000 0.01220 0.00000 0.00176 0.00309 0.00724 0.00110 0.00386 0.00222 
3.75 0.03987 0.00000 0.00043 0.06838 0.00258 0.01287 0.00378 0.00179 0.00000 0.01290 
3.74-3.71 0.00000 0.00000 0.00000 0.00000 0.00000 0.00994 0.00000 0.00000 0.00000 0.00000 
3.63 0.00559 0.00530 0.01025 0.00379 0.00436 0.00335 0.00756 0.00323 0.00414 0.00588 
3.62 0.01518 0.01204 0.01759 0.01429 0.01175 0.00948 0.01767 0.01180 0.00614 0.01451 
3.6 0.01152 0.00660 0.01091 0.01238 0.00659 0.00675 0.01883 0.00601 0.00455 0.01205 
3.34 0.00620 0.00799 0.01587 0.00543 0.00601 0.00147 0.01489 0.00306 0.00282 0.00345 
3.29 0.00056 0.00000 0.00000 0.00000 0.00110 0.00000 0.00823 0.00176 0.00170 0.00134 
3.27 0.01015 0.01650 0.00107 0.00000 0.01411 0.00999 0.02512 0.01043 0.00765 0.01132 
3.26 0.00000 0.01680 0.00000 0.00251 0.01389 0.01485 0.02303 0.01562 0.01315 0.01230 
3.24 0.03820 0,00000 0.02180 0.01878 0.00000 0.00000 0.01070 0.00405 0.00000 0.00866 
3.22 0.00660 0.00944 0.00000 0.01273 0.02871 0.01564 0.03487 0.00552 0.01301 0.01691 
3.2 0.02099 0.01190 0.01699 0.01932 0.02597 0.00458 0.03401 0.01602 0.01404 0.01940 
3.15-3.1 0.03229 0.00000 0.07126 0.04399 0.00609 0.00000 0.01180 0.01775 0.00000 0.00561 
3.09-3.05 0.00728 0.00000 0.04379 0.05184 0.00127 0.00000 0.00000 0.00170 0.00000 0.00268 
3.03 0.01156 0.00000 0.07289 0.02561 0.01392 0.01084 0.00630 0.01163 0.00748 0.01524 
2.71 0.00216 0.00000 0.01146 0.01000 0.00195 0.00000 0.00233 0.00699 0.01267 0.00364 
2.68 0.00000 0.00000 0.00625 0.01832 0.00353 0.00000 0.00692 0.00842 0.01061 0.00939 
2.55 0.00165 0.00000 0.01052 0.00707 0.00254 0.00062 0.00651 0.00930 0.00185 0.00698 
2.52 0.00659 0.00000 0.00844 0.02735 0.00353 0.00090 0.00754 0.00917 0.00102 0.01314 
2.45-2.43 0.00157 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00242 0.00000 
2.42-2.4 0.00097 0.00000 0.00119 0.00109 0.00251 0.00551 0.00175 0.00102 0.00000 0.00205 
2.36 0.00211 0.00000 0.00000 0.00000 0.00520 0.00000 0.00231 0.00068 0.00000 0.00134 
2.35 0.00000 0.00000 0.00523 0.00073 0.00417 0.01663 0.00429 0.00339 0.00232 0.00352 
2.34 0.00522 0.00000 0.00000 0.00289 0.00948 0.00000 0.00787 0.00379 0.00000 0.00511 
2.33-2.3 0.00384 0.00000 0.00432 0.01152 0.00000 0.01230 0.00000 0.00161 0.00000 0.00000 
1.48-1.46 0.00202 0.00000 0.00688 0.00305 0.00506 0.01540 0.01325 0.00227 0.00749 0.00715 
1.34-1.32 0.04700 0.00000 0.09321 0.12368 0.10976 0.11945 0.13979 0.09176 0.09347 0.10916 
1.28 0.01116 0.00000 0.02466 0.07138 0.09506 0.02698 0.05279 0.07373 0.13369 0.00746 
1.2 0.00264 0.00000 0.00227 0.00000 0.00000 0.00086 0.02582 0.00000 0.00144 0.00033 
0.96-0.93 0.00283 0.00000 0.01190 0.01614 0.01171 0.01643 0.01534 0.01369 0.00631 0.01896 
0.9 0.00234 0.00000 0.00889 0.00685 0.03072 0.00240 0.00445 0.00615 0.05283 0.00585 
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Table A5: Spectral intensities in samples 21 - 30 
Roi / Sample 21 22 23 24 25 26 27 28 29 30 
4.14-4.11 000321 0.02608 0.02793 0.01813 0.01170 0.02353 0.02281 0.02262 0.02722 0.01435 
4.05 0.00128 0.01847 0.02444 0.01459 0.02067 0.01307 0.01510 0.01389 0.02879 0.01445 
3.99-3.96 0.00339 0.00000 0.00949 0.00363 0.00031 0.00075 0.00097 0.00000 0.00179 0.00537 
3.94-3.93 0.00548 0.00621 0.02174 0.00379 0.00253 0.00876 0.00479 0.00820 0.00936 0.01237 
3.78 0.00293 0.00321 0.00000 0.00495 0.00570 0.00622 0.00231 0.00912 0.00468 0.00389 
3.75 0.00370 0.00200 0.00180 0.00228 0.00245 0.00349 0.00054 0.00338 0.00191 0.01118 
3.74-3.71 0.01465 0.00000 0.00000 0.00000 0.00000 0.00531 0.00000 0.00000 0.00000 0.02584 
3.63 0.00395 0.00604 0.00378 0.00349 0.00937 0.01083 0.01666 0.00426 0.02922 0.01395 
3.62 0.00755 0.01409 0.01389 0.00808 0.01707 0.00699 0.00934 0.01394 0.00000 0.01711 
36 0.00600 0.01152 0.01383 0.00626 0.01916 0.00271 0.00712 0.01052 0.01647 0.02497 
3.34 0.00132 0.00317 0.00000 0.00168 0.01018 0.00469 0.00580 0.00430 0.01002 0.00413 
3.29 0.00094 0.00196 0.00000 0.00239 0.00330 0.00134 0.00513 0.00238 0.00444 0.00586 
3.27 0.00471 0.00925 0.00000 0.00208 0.00581 0.00547 0.00866 0.01409 0.01466 0.00778 
3.26 0.00542 0.05014 0.00000 0.01658 0.02375 0.01833 0.00822 0.02623 0.01165 0.00875 
3.24 0.00381 0.00000 0.00000 0.00120 0.00702 0.00483 0.00524 0.00000 0.00834 0.00614 
3.22 0.00773 0.02838 0.00000 0.00703 0.01741 0.01018 0.01121 0.01767 0.00637 0.00940 
32 0.00887 0.02147 0.00000 0.00043 0.03266 0.01224 0.01370 0.01154 0.01542 0.01238 
3.15-3.1 0.00035 0.00101 0.00000 0.00563 0.07256 0.04165 0.02799 0.00504 0.00294 0.01490 
3.09-3.05 0.00000 0.00000 0.00000 0.00519 0.00122 0.00129 0.02180 0.00000 0.00355 0.00172 
303 0.00469 0.01666 0.00000 0.00435 0.01334 0.01264 0.00303 0.02480 0.02404 0.00550 
2.71 0.00197 0.00089 0.00000 0.00931 0.01017 0.00235 0.01288 0.00513 0.01801 0.01076 
2.68 0.00104 0.00820 0.00000 0.01095 0.00013 0.00000 0.00000 0.00172 0.02288 0.00000 
2.55 0.00272 0.00498 0.00000 0.00996 0.01235 0.00421 0.00783 0.00545 0.01402 0.00203 
2.52 0.00140 0.00992 0.00000 0.00691 0.01135 0.00272 0.00000 0.00909 0.01504 0.00166 
2.45-2.43 0.00000 0.00000 0.00000 0.00259 0.00264 0.00229 0.00103 0.00052 0.00000 0.00215 
2.42-2.4 0.00000 0.00000 0.00000 0.00205 0.00066 0.00000 0.00000 0.00356 0.00000 0.00639 
2.36 0.00196 0.00267 0.00000 0.00134 0.01099 0.00559 0.00328 0.00240 0.00767 0.01915 
2.35 0.00181 0.00319 0.00000 0.00628 0.00000 0.00346 0.00743 0.00575 0.00000 0.00000 
2.34 0.00280 0.00462 0.00000 0.00000 0.00197 0.00000 0.00000 0.00000 0.01624 0.00000 
2.33-2.3 0.00000 0.00000 0.00000 0.00364 0.01461 0.00982 0.00111 0.00792 0.00000 0.02840 
1.48-1.46 0.00121 0.00892 0.00000 0.00259 0.00767 0.00537 0.01004 0.00715 0.00780 0.00059 
1.34-1.32 0.08476 0.12480 0.00000 0.07110 0.05916 0.07489 0.06441 0.10963 0.12399 0.06112 
1.28 0.09282 0.01348 0.00000 0.05935 0.05350 0.01511 0.02401 0.07369 0.06723 0.08683 
1.2 0.00128 0.00000 0.00000 0.00000 0.01362 0.00022 0.00932 0.00000 0.06307 0.01187 
0.96-0.93 0.00621 0.01083 0.00000 0.01542 0.00772 0.00800 0.00870 0.00859 0.01416 0.01768 
0.9 0.01010 0.01085 0.00000 0.00291 0.00335 0.00000 0.01066 0.00382 0.02046 0.03727 
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Table A6: Spectral intensities in samples 31-40 
ROI 31 32 33 34 35 36 37 38 39 40 
4.14-4.11 0.02748 0.01776 0.01125 0.01300 0.02373 0.01075 0.01428 0.01470 0.02681 0.01504 
4.05 0.03705 0.00000 0.01359 0.00744 0.01341 0.02103 0.00895 0.01130 0.00455 0.01812 
3.99-3.96 0.00376 0.00309 0.00228 0.00187 0.00044 0.00028 0.00037 0.00000 0.00382 0.00077 
3.94-3.93 0.00823 0.00272 0.01037 0.00075 0.00549 0.00456 0.00353 0.00627 0.00633 0.00532 
3.78 0.01076 0.00015 0.00607 0.00216 0.00416 0.00353 0.00209 0.00330 0.00292 0.00641 
3.75 0.00404 0.00000 0.00646 0.00170 0.00226 0.00057 0.00029 0.00142 0.00162 0.00082 
3.74-3.71 0.01116 0.00192 0.02155 0.00355 0.00085 0.00071 0.00000 0.01426 0.00000 0.00383 
3.63 0.00559 0.00162 0.00200 0.00777 0.02087 0.00792 0.00964 0.00399 0.00419 0.01264 
3.62 0.01603 0.00089 0.01560 0.00700 0.02558 0.01578 0.01302 0.00789 0.01385 0.01748 
3.6 0.00857 0.00975 0.01372 0.00360 0.00435 0.00733 0.00325 0.00310 0.00156 0.01306 
3.34 0.00331 0.03402 0.00000 0.00155 0.01024 0.00150 0.00041 0.00149 0.00353 0.00504 
3.29 0.00137 0.01295 0.00000 0.00392 0.00897 0.00053 0.00157 0.00075 0.00687 0.00245 
3.27 0.00979 0.02100 0.00000 0.00409 0.01172 0.00435 0.00404 0.00741 0.01046 0.00608 
3.26 0.02271 0.01922 0.00000 0.00525 0.01231 0.01443 0.01084 0.00000 0.01146 0.01052 
3.24 0.00000 0.02048 0.00000 0.00345 0.00893 0.00572 0.00065 0.01727 0.01275 0.00689 
3.22 0.01249 0.00397 0.00000 0.00591 0.02233 0.00615 0.00798 0.01034 0.01483 0.00823 
3.2 0.01078 0.01144 0.00000 0.00721 0.02605 0.00745 0.00686 0.01220 0.01509 0.01457 
3.15-3.1 0.00641 0.00000 0.00000 0.00844 0.02683 0.02570 0.00115 0.00363 0.00053 0.03223 
3.09-3.05 0.02494 0.01526 0.00000 0.00096 0.01360 0.00071 0.01145 0.00104 0.01082 0.00323 
3.03 0.00980 0.00000 0.00000 0.00317 0.01507 0.01044 0.00138 0.01204 0.00159 0.00208 
2.71 0.00905 0.00245 0.00000 0.00409 0.02081 0.01342 0.01644 0.00798 0.00236 0.01080 
2.68 0.01340 0.00251 0.00000 0.00000 0.02540 0.00988 0.01560 0.00231 0.00191 0.00965 
2.55 0.00927 0.00129 0.00000 0.00129 0.01604 0.00545 0.01668 0.00757 0.00201 0.01217 
2.52 0.00527 0.00338 0.00000 0.00177 0.01841 0.00496 0.01829 0.00310 0.00243 0.00178 
2.45-2.43 0.00000 0.00000 0.00000 0.00000 0.00000 0.00044 0.00077 0.00068 0.00328 0.00000 
2.42-2.4 0.00770 0.00584 0.00000 0.00000 0.00000 0.00040 0.00017 0.00018 0.00000 0.00000 
2.36 0.00063 0.00339 0.00000 0.00577 0.00630 0.00425 0.00346 0.00305 0.00342 0.00243 
2.35 0.00194 0.00647 0.00000 0.00306 0.00000 0.00335 0.00223 0.00365 0.00000 0.00172 
2.34 0.00455 0.01035 0.00000 0.00000 0.00869 0.00000 0.00078 0.00000 0.00301 0.00000 
2.33-2.3 0.01838 0.00846 0.00000 0.00983 0.01298 0.00709 0.00382 0.00423 0.00310 0.00000 
1.48-1.46 0.00495 0.00000 0.00000 0.00295 0.00720 0.00419 0.00465 0.00543 0.00248 0.00350 
1.34-1.32 0.09820 0.07400 0.00000 0.05067 0.09751 0.06178 0.06864 0.05167 0.08219 0.05444 
1.28 0.03550 0.04424 0.00000 0.08703 0.10690 0.02427 0.06987 0.07582 0.14441 0.02116 
1.2 0.00067 0.00918 0.00000 0.00000 0.05177 0.00195 0.01348 0.00527 0.00910 0.00250 
0.96-0.93 0.00823 0.01261 0.00000 0.00231 0.00972 0.00752 0.00330 0.00494 0.00629 0.02704 
0.9 0.01260 0.01155 0.00000 0.00995 0.01605 0.00256 0.00364 0.00405 0.00384 0.01373 
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Table A7: Spectral intensities in samples 41-46 
ROI 41 42 43 44 45 46 
4.14-4.11 0.00557 0.01659 0.02709 0.02361 0.01180 0.01990 
4.05 0.01562 0.01359 0.02887 0.02120 0.00732 0.01513 
3.99-3.96 0.00673 0.00191 0.00136 0.00346 0.00349 0.00317 
3.94-3.93 0.01158 0.00611 0.01518 0.00960 0.00361 0.00933 
3.78 0.02570 0.00322 0.00245 0.00338 0.00251 0.00389 
3.75 0.00619 0.00035 0.00131 0.00107 0.00081 0.00347 
3.74-3.71 0.03482 0.00000 0.00000 0.00000 0.00000 0.00000 
3.63 0.00150 0.00876 0.00508 0.02564 0.00578 0.00765 
3.62 0.00811 0.01281 0.01294 0.01166 0.00336 0.00407 
3.6 0.01286 0.00660 0.00550 0.00202 0.00315 0.00172 
3.34 0.00300 0.00265 0.00581 0.00599 0.00145 0.00204 
3.29 0.00247 0.00167 0.00000 0.00227 0.00053 0.00118 
3.27 0.00507 0.00578 0.00590 0.00716 0.00225 0.00612 
3.26 0.00578 0.01447 0.00004 0.01615 0.00537 0.00999 
3.24 0.00212 0.00241 0.01023 0.00395 0.00429 0.01152 
3.22 0.01192 0.00826 0.00445 0.00518 0.01268 0.00960 
3.2 0.00738 0.00595 0.00564 0.00641 0.00931 0.00751 
3.15-3.1 0.00382 0.02095 0.02813 0.01649 0.00000 0.00284 
3.09-3.05 0.00095 0.00130 0.01729 0.01160 0.00001 0.00000 
3.03 0.00576 0.01024 0.00801 0.01349 0.00649 0.00341 
2.71 0.00447 0.03292 0.01081 0.00381 0.00125 0.00576 
2.68 0.00546 0.00878 0.00186 0.00187 0.00127 0.00743 
2.55 0.00539 0.01952 0.00850 0.00259 0.00107 0.00492 
2.52 0.00286 0.02285 0.00266 0.00340 0.00017 0.00535 
2.45-2.43 0.00000 0.00000 0.00180 0.00000 0.00000 0.00172 
2.42-2.4 0.00119 0.00000 0.00431 0.00000 0.00023 0.00313 
2.36 0.00156 0.00341 0.00186 0.00703 0.00588 0.00105 
2.35 0.00369 0.00000 0.00630 0.00000 0.00547 0.00246 
2.34 0.00228 0.00000 0.00000 0.00429 0.00371 0.00604 
2.33-2.3 0.00034 0.00584 0.00000 0.00785 0.00764 0.00292 
1.48-1.46 0.00523 0.00844 0.00393 0.01071 0.00980 0.00882 
1.34-1.32 0.06154 0.07592 0.08922 0.09819 0.05053 0.09893 
1.28 0.00687 0.01189 0.00062 0.06018 0.09210 0.01837 
1.2 0.00000 0.00102 0.00000 0.00000 0.00036 0.00391 
0.96-0.93 0.01063 0.00937 0.00575 0.01267 0.01019 0.00843 
0.9 0.00314 0.00772 0.00036 0.00864 0.00446 0.00431 
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A.3 Graphs for Correlations of Spectral Intensities and CaE% determined by 
QIAP in 34 Additional Regions of Interest 
Figure A1: Graphs depicting the non-significant correlations of relative spectral intensities in 
regions 4.14 – 4.11 ppm (p = 0.2601), 4.05 ppm (p = 0.5958), 3.99-3.96ppm (p = 0.9801),  
3.94 – 3.93 ppm (p = 0.2578), 3.78 ppm (p = 0.7227) and 3.75 ppm (p = 0.7545) 
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Figure A2: Graphs depicting the non-significant correlations of relative spectral intensities in 
regions 3.74 – 3.71 (p = 0.6097), 3.63 ppm (p = 0.4631), 3.62 ppm (p = 0.4631), 3.6 ppm 
(p = 0.3310), 3.34 ppm (p = 0.8102) and 3.29 ppm (p = 0.6998) 
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Figure A3: Graphs depicting the non-significant correlations of relative spectral intensities in 
regions 3.27 ppm (p = 0.5405), 3.26 ppm (p = 0.6705), 3.24 ppm (p = 0.2549), 3.2 ppm (p = 0.4686), 
3.15 – 3.1 ppm (p= 0.7938) and 3.09 – 3.05 ppm (p = 0.6025) 
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Figure A4: Graphs depicting the non-significant correlations of relative spectral intensities in 
regions 3.03 ppm (p = 0.7427), 2.71 ppm (p = 0.7122), 2.55 ppm (p = 0.9801), 2.52 ppm (p = 0.2578), 
2.45 – 2.43 ppm (p = 0.7227) and 2.42 – 2.4 ppm (p = 0.7545) 
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Figure A5: Graphs depicting the non-significant correlations of relative spectral intensities in 
regions 2.63 ppm (p = 0.9285), 2.35 ppm (p = 0.8953), 2.34 ppm (p = 0.1294), 2.33 – 2.3 ppm  
(p = 0.7448), 1.48 – 1.46 ppm (p= 0.7828) and 1.34 – 1.32 ppm (p = 0.5334) 
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Figure A6: Graphs depicting the non-significant correlations of relative spectral intensities in 
regions 1.28 ppm (p= 0.1901), 1.2 ppm (p = 0.0740), 30.96 – 0.93 ppm (p = 0.9754), and 0.9 ppm 
 (p = 0.0633) 
p = 0.1901 
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